Reading List
HEMATOLOGY READING LIST
1. NORMAL HEMATOPOIESIS
Origin of Hematopoiesis
Yolk-sac hematopoiesis: the first blood cells of mouse and man.
Palis J, Yoder MC. Exp Hematol. 2001;29:927-936.
Basic Hematopoietic Stem Cell Concepts
Stem cells: units of development, units of regeneration, and units in evolution.
Weissman IL. Cell. 2000;100:157-168.
A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.
Till JE, McCulloch EA. Radiat Res. 1961;14:213-222.
Primitive hematopoietic stem cells: direct assay of most productive population by competitive repopulation with simple binomial, correlation and covariance calculations.
Harrison DE, Jordan CT, Zhong RK, Astle CM. Exp Hematol. 1993;21:206-219.
Clonal and systemic analysis of long-term hematopoiesis in the mouse.
Jordan CT, Lemishka IR. Genes Dev. 1990;4:220-232.
Lineage commitment and maturation in hematopoietic cells: the case for extrinsic regulation.
Metcalf D. Blood. 1998;92:345-348.
Evidence that hematopoiesis may be a stochastic process in vivo.
Abkowitz JL, Catlin SN, Guttorp P. Nature Med. 1996;2:190-197.
Plasticity of adult stem cells.
Wagner AJ, Weissman IL. Cell. 2004;116:639-648.
Assays for Human Hematopoietic Stem Cells
Engraftment of immune-deficient mice with human hematopoietic stem cells.
Kamel-Reid S, Dick JE. Science. 1988;242:1706-1709.
Engraftment and long-term expression of human fetal hematopoietic stem cells in sheep following transplantation in utero.
Zanjani ED, Pallavicini MG, Ascensao JL, et al. J Clin Invest. 1992;89:1178-1188.
Assays for Committed Hematopoietic Progenitor Cells
Functional characterization of individual human hematopoietic stem cells cultured at limiting dilutions on supportive marrow stromal layers.
Sutherland HJ, Lansdorp PM, Henkelman DH, Eaves AC, Eaves CJ . Proc Natl Acad Sci U S A. 1990;87:3584-3588.
Pure and mixed erythroid colony formation in vitro stimulated by spleen conditioned medium with no detectable erythropoietin activity.
Johnson GR, Metcalf D. Proc Natl Acad Sci U S A. 1977;74:3879-3882.
Hematopoietic Microenvironment
Matrix molecule interactions with hematopoietic stem cells.
Yoder MC, Williams DH. Exp Hematol. 1995;23:961-967.
Hematopoietic Growth Factors
Hematopoietic regulators: redundancy or subtlety?
Metcalf D. Blood. 1993;82:3515-3523.
Erythropoietin.
Krantz SB. Blood. 1991;77:419-434.
Control of granulocytes and macrophages: molecular, cellular and clinical aspects.
Metcalf D. Science. 1991;254:529-533.
Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.
Kuter DJ, Begley CG. Blood. 2002;100:3457-3469.
Stem cell factor and hematopoiesis.
Broudy VC. Blood. 1997;90:1345-1364.
2. Nutritional Deficiencies and Anemia of Chronic Disease
Diagnosis
Discriminating between iron deficiency anemia and anemia of chronic disease using traditional indices of iron status vs. transferring receptor concentration.
Wians FH Jr, Urban JE, Keffer JH, Kroft SH. Am J Clin Pathol. 2001;115:112-118.
Clinical spectrum and diagnosis of cobalamin deficiency.
Stabler SP, Allen RH, Savage DG, Lindenbaum J. Blood. 1990;76:871-881.
Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations.
Naurath HG, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Lancet. 1995;346:85-89.
Pathophysiology
Cytokine-mediated regulation of iron transport in human monocytic cells.
Ludwiczek S, Aigner E, Weiss G. Blood. 2003;101:4148-4154.
Prevalence of anemia in persons greater than 65 and older in the United States: evidence for a high rate of unexplained anemia.
Guralnik J, Eisenstaedt R, Ferrucci L, Klein H, Woodman R. Blood. 2004;104:2263-2268.
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.
Ganz T. Blood. 2003;102:783-788.
Treatment
Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency (HIV) infection and zidovudine therapy.
Henry DH, Bealll GN, Benson CA, et al. Ann Int Med. 1992;117:739-748.
Erythropoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials.
Seidenfeld J, Piper M, Flamm C, et al. J Natl Cancer Inst. 2001;93:1204-1214.
Effective treatment of cobalamin deficiency with oral cobalamin.
Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. Blood. 1998;92:1191-1198.
Erythropoetin therapy.
Goodnough L, Monk T, Andriole G. N Eng J Med. 1997;336:933-938.
Review
Medical progress: anemia of chronic disease.
Weiss G, Goodnough L. N Eng J Med. 2005;352:1011-1023.
Recent developments in the anemia of chronic disease.
Means RT Jr. Curr Hematol Rep. 2003;2:116-121.
Pernicious anemia.
Toh BH, van Driel IR, Gleeson PA. N Eng J Med. 1997;337:1441-1448.
3. RED CELL APLASIA AND HYPOPLASIA
Red Cell Aplasia
CONGENITAL
Hypoplastic anemia.
Diamond LK, Blackfan KD Am J Dis Child. 1938;56:464.
Inherited bone marrow failure syndrome.
Alter BP. In: Nathan DG, Orkin SH, Look AT, Ginsburg D, eds. Nathan and Oski’s Hematology of Infancy and Childhood, 6th ed. Philadelphia, PA: WB Saunders; 2003:280-365.
ACQUIRED
Transient erythroblastopenia of childhood: prospective study of fifty patients.
Cherrick I, Karayalcin G, Lanzkowsky P. Am J Pediatr Hematol Oncol. 1994;16:320.
The bone marrow failure syndromes.
Alter BP, Young NS. In: Nathan DG, Orkin SH, Look AT, Ginsburg D, eds. Nathan and Oski’s Hematology of Infancy and Childhood, 6th ed. Philadelphia, PA: WB Saunders; 2003.
Red Cell Hypoplasia
ANEMIA OF RENAL DISEASE
Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial.
Escgbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. N Engl J Med. 1987;316:73-78.
N(G)-monomethyl-L-arginine inhibits erythropoietin gene expression by stimulating GATA-2.
Tarumoto T, Imagawa S, Ohmine K, et al. Blood. 2000;96:1716-1722.
National Kidney Foundation: dialysis outcome quality initiative: development of methodology for clinical practice guidelines.
Levin N, Eknoyan G, Pipp M, Steinberg E. Nephrol Dial Transplant. 1997;12:2060-2063.
ANEMIA OF ENDOCRINE DISORDERS
Thyroid hormones stimulate erythropoiesis in vitro.
Golde DW, Bersch N, Chopra IJ, Cline MJ. Br J Haematol. 1977;37:173-177.
Anemia and secondary hyperparathyroidism.
Zingraff T, Drueke P, Marie NK, Man P, Jungers P, Bordier J. Arch Intern Med. 1978;138:1650-1652.
ANEMIA SECONDARY TO MALNUTRITION AND STARVATION
Hematologic changes in anorexia nervosa.
Amrein P, Friedman R, Kosinski K, Ellman L. JAMA. 1979;241:2190-2191.
IRON DEFICIENCY ANEMIA
Discriminating between iron deficiency anemia and anemia of chronic disease using traditional indices of iron status versus transferrin receptor concentration.
Wians FH, Urban JE, Keffer JH, Kroft SH. Am J Clin Pathol. 2001;115:112-118.
The rationale for treating iron deficiency anemia.
Crosby W. Arch Intern Med. 1984;144:471-472.
ANEMIA SECONDARY TO MARROW INFILTRATION
Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration.
Oster W, Herrmann F, Gamm H, Zeile G, Lindemann A, Muller G, Brune T, Kraemer HP, Mertelsmann R. J Clin Oncol. 1990;8:956-962.
4. MYELODYSPLASTIC SYNDROMES
Pathophysiology
Granulopoiesis in acute myeloid leukemia and preleukemia.
Greenberg PL, Nichols W, Schrier SL. N Engl J Med. 1971;284:1225-1231.
Distinct haematological disorder with deletion of the long arm of no. 5 chromosome.
van den Berghe H, Cassiman J-J, Fryns J-P, Michaux J-L, Sokal G. Nature. 1974;251:437-438.
Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features.
Kantarjian HM, Keating MJ, Walters RS, et al. J Clin Oncol. 1986;4:1748-1757.
Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin.
Janssen JWG, Buschle M, Layton M, et al. Blood. 1989;73;248-254.
Diagnosis
Preleukemic acute human leukemia.
Block M, Jacobson LO, Bethard WF. JAMA. 1953;152:1018-1028.
Proposals for the Classification of the Myelodysplastic Syndromes.
Bennett JM, Catovsky D, Daniel MT, et al: the French- American-British (FAB) Cooperative Group. Br J Haematol. 1982;51:189-199.
Treatment
Maintenance treatment of patients with myelodysplatic syndromes using recombinant human granulocyte colony-stimulating factor.
Negrin RS, Haeuber DH, Nagler A, et al. Blood. 1990;76:36-43.
Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome.
Anderson JE, Appelbaum FR, Fisher LD, et al.. Blood. 1993;82:677-681.
Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program.
Castro-Malaspina H, Harris RE, Gajewski J, et al. Blood. 2002;99:1943-1951.
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes.
Raza A, Gezer S, Mundle S, et al. Blood. 1995;86:268-276.
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes.
Greenberg P, Cox C, LeBeau MM, et al. Blood. 1997;89:2079-2088.
Antithymocyte globulin for patients with myelodysplastic syndrome.
Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Br J Haematol. 1997;9:699-705.
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.
Saunthararajah Y, Nakamura R, Nam JM, et al. Blood. 2002;100:1570-1574.
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al: Scandinavian MDS Group. Br J Haematol. 2003;120:1037-1046.
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.
Casadevall N, Durieux P, Dubois S, et al. Blood. 2004;104:321-327.
Efficacy of lenalidomide in myelodysplastic syndromes.
List A, Kurtin S, Roe DJ, et al. N Engl J Med. 2005;352:549-557.
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group.
Silverman LR, Demakos EP, Peterson BL, et al. J Clin Oncol. 2002;20:2429-2440.
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
Kornblith AB, Herndon JE 2nd, Silverman LR, et al. J Clin Oncol. 2002;20:2441-2452.
Review
The myelodysplastic syndrome(s): a perspective and review highlighting current controversies.
Steensma DP, Tefferi A. Leuk Res. 2003;27:95-120.
Prediction of adverse outcomes in children with sickle cell disease.
Miller ST, Sleeper LA, Pegelow CH, et al. N Engl J Med. 2000;342:83-89.
Survival of children with sickle cell disease.
Quinn CT, Rogers ZR, Buchanan GR. Blood. 2004;103:4023-4027.
Complications
Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study.
Adams RJ, Brambilla DJ, Granger S, et al. Blood. 2004;103:3689-3694.
Psychopathology in sickle cell disease.
Alao AO, Dewan MJ, Jindal S, Effron M. West Afr J Med. 2003;22:334-337.
Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease.
Miller ST, Macklin EA, Pegelow CH, et al. J Pediatr. 2001;139:385-390.
Pulmonary manifestations of sickle cell disease.
Siddiqui AK, Ahmed S. Postgrad Med J. 2003;79:384-390.
Treatment
Stroke prevention trial in sickle cell anemia.
Adams RJ, McKie VC, Brambilla D, et al. Control Clin Trials. 1998;19:110-129.
Managing sickle cell disease.
Claster S, Vichinsky EP. BMJ. 2003;327:1151-1155.
Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia.
Miller ST, Wright E, Abboud M, et al. J Pediatr. 2001;139:785-789.
Gene therapy for hemoglobinopathies: are we there yet?
Puthenveetil G, Malik P. Curr Hematol Rep. 2004;3:298-305.
Therapies to increase fetal hemoglobin in sickle cell disease.
Steinberg MH. Curr Hematol Rep. 2003;2:95-101.
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
Steinberg MH, Barton F, Castro O, et al. JAMA. 2003;289:1645-1651.
Pathophysiological-based approaches to treatment of sickle cell disease.
Steinberg MH, Brugnara C. Annu Rev Med. 2003;54:89-112.
Review
Sickle cell disease.
Buchanan GR, DeBaun MR, Quinn CT, Steinberg MH. Hematology (Am Soc Hematol Educ Program). 2004:35-47.
Fixler J, Styles L.
Pediatr Clin North Am. 2002;49:1193-1210, vi.
6. THALASSEMIAS
Pathophysiology
Pathophysiology of alpha- and beta-thalassemia: therapeutic implications.
Rund D, Rachmilewitz E. Semin Hematol. 2001;38:343-349.
Thalassemia: pathophysiology of red cell changes.
Schrier SL. Annu Rev Med. 1994;45:211-218.
Pathophysiology of thalassaemia.
Weatherall DJ. Baillieres Clin Haematol. 1998;11:127-146.
Genetic factors affecting clinical severity in beta-thalassemia syndromes.
Winichagoon P, Fucharoen S, Chen P, Wasi P. J Pediatr Hematol Oncol. 2000;22:573-580.
Diagnosis
Molecular diagnosis of haemoglobin disorders.
Clark BE, Thein SL. Clin Lab Haematol. 2004;26:159-176.
Screening and genetic diagnosis of haemoglobin disorders.
Old JM. Blood Rev. 2003;17:43-53.
Treatment
New developments in iron chelators.
Cunningham MJ, Nathan DG. Curr Opin Hematol. 2005;12:129-134.
Iron-chelating therapy and the treatment of thalassemia.
Olivieri NF, Brittenham GM. Blood. 1997;89:739-761.
New strategies in the treatment of the thalassemias.
Schrier SL, Angelucci E. Annu Rev Med. 2005;56:157-171.
Review
Thalassemia.
Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Hematology (Am Soc Hematol Educ Program). 2004:14-34.
Thalassemia: current approach to an old disease.
Lo L, Singer ST. Pediatr Clin North Am. 2002;49:1165-1191.
7. AUTOIMMUNE HEMOLYTIC ANEMIA
Pathophysiology
Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia.
Myint H, Copplestone JA, Orchard J, et al. Br J Haematol. 1995;91:341-344.
Mechanisms of immunological tolerance loss versus erythrocyte self-antigens and autoimmune hemolytic anemia.
Fagiolo E, Toriani-Terenzi C. Autoimmunity. 2003;36:199-204.
Drug-induced hemolytic anemias: increasing complications to therapeutic interventions.
Wright MS. Clin Lab Science. 1999;12:115-118.
NIH conference: pathophysiology of immune hemolytic anemia.
Ann Inter Med. 1977;87:210-222.
Diagnosis
A new test for the detection of weak and “incomplete” Rh agglutinins.
Coombs RRA, Mourant AE, Rrace RR. Br J Exp Path. 1945;26:255-266.
The predictive value of serum haptoglobin in hemolytic disease.
Marchand A, Galen RS, Van Lente F. JAMA. 1980;243:1909-1911.
Treatment
Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.
Zecca M, Nobili B,Ramenghi U,et al. Blood. 2003;101:3857-3861.
Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura.
Howard J, Hoffbrand AV, Prentice HG, Mehta A. Br J Haematol. 2002;117:712-715.
Review
The acute and transient nature of idiopathic immune hemolytic anemia in childhood.
Buchanan GR, Boxer LA, Nathan DG. J Pediatr. 1976;88:780-783.
Autoimmune hemolytic anemia.
Gehrs BC , Friedberg RC. Am J Hematol. 2002;69:258-271.
Immune haemolytic disease: the autoimmune haemolytic anaemias.
Pirofsky B. Clin Haematol. 1975;4:167.
The variability of hemolysis in the cold agglutinin syndrome.
Rosse WF, Adams JP. Blood. 1980;56:409-416.
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.
Mauro FR, Foa R, Cerretti R, et al. Blood. 2000;95:2786-2792.
8. RBC MEMBRANE DISORDERS
Pathophysiology
Molecular basis of red cell membrane disorders.
Delaunay J. Acta Haematol. 2002;108:210-218.
Update on the clinical spectrum and genetics of red blood cell membrane disorders.
Gallagher PG. Curr Hematol Rep. 2004;3:85-91.
Review
The hereditary stomatocytoses: genetic disorders of the red cell membrane permeability to monovalent cations.
Delaunay J. Semin Hematol. 2004;41:165-172.
Red blood cell membrane defects.
Iolascon A, Perrota S, Stewart GW. Rev Clin Exp Hematol. 2003;7:22-56.
Guidelines for the diagnosis and management of hereditary spherocytosis.
Bolton-Maggs PH, Stevens RF, Dodd NJ, Lamont G, Tittensor P, King MJ. Br J Haematol. 2004;126:455-474.
Hereditary spherocytosis—defects in proteins that connect the membrane skeleton to the lipid bilayer.
Eber S, Lux SE. Semin Hematol. 2004;41:118-141.
Hereditary elliptocytosis: spectrin and protein 4.1R.
Gallagher PG. Semin Hematol. 2004;41:142-164.
9. MICROANGIOPATHIC HEMOLYTIC ANEMIAS
Pathophysiology
Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.
Moake JL, Rudy CK, Troll JH, et al. N Engl J Med. 1982;307:1432-1435.
The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.
Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. J Infect Dis. 1985;151:775-782.
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Furlan M, Robles R, Galbusera M, et al. N Engl J Med. 1998;339:1578-1584.
Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
Tsai HM, Lian EC. N Engl J Med. 1998;339:1585-1594.
Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.
Levy GG, Nichols WC, Lian EC, et al. Nature. 2001;413:488-494.
Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.
Richards A, Kemp EJ, Liszewski MK, et al. Proc Natl Acad Sci U S A. 2003;100:12966-12971.
Genetic studies into inherited and sporadic hemolytic uremic syndrome.
Warwicker P, Goodship TH, Donne RL, et al. Kidney Int. 1998;53:836-844.
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma.
George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB. Transfusion. 2004;44:294-304.
Epidemiology
Epidemiology of Escherichia coli O157:H7 outbreaks: United States, 1982-2002.
Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL. Emerg Infect Dis. 2005;11:603-609.
Diagnosis
Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature.
Amorosi EL, Ultmann JE. Medicine. 1966;45:139-159.
ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.
Vesely SK, George JN, Lammle B, et al. Blood. 2003;102:60-68.
Treatment
Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.
Rock GA, Shumak KH, Buskard NA, et al. N Engl J Med. 1991;325:393-397.
Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis.
Safdar N, Said A, Gangnon RE, Maki DG. JAMA. 2002;288:996-1001.
Prognosis
Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.
Lesesne JB, Rothschild N, Erickson B, et al. J Clin Oncol. 1989;7:781-789.
Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group.
Shumak KH, Rock GA, Nair RC. Ann Intern Med. 1995;122:569-572.
Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases.
Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Ann Intern Med. 1998;128:541-544.
Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.
Garg AX, Suri RS, Barrowman N, et al. JAMA. 2003;290:1360-1370.
Review Articles
Thrombotic microangiopathy during pregnancy.
McCrae KR, Cines DB. Semin Hematol. 1997;34:148-158.
How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
George JN. Blood. 2000;96:1223-1229.
Thrombotic microangiopathies.
Moake JL. N Engl J Med. 2002;347:589-600.
10. ACQUIRED NON-IMMUNE HEMOLYTIC ANEMIAS
Diagnosis
Red blood cell enzymes and their clinical application.
Fujii H, Miwa S. Adv Clin Chem. 1999;33:1-54.
Pathophysiology
Paroxysmal nocturnal hemoglobinuria as a molecular disease.
Rosse WF. Rev in Mol Med. 1997;76:63-93.
Natural history of paroxysmal nocturnal hemoglobinuria.
Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. N Eng J Med. 1995;333:1253-1258.
Mechanisms of hemolysis in liver disease.
Morse EE. Ann of Clin & Lab Science. 1990;20:169-174.
The role of the spleen in hemolysis.
Ferrant A. Clin in Haem. 1983;12:489-504.
Hemolysis and infection: categories and mechanisms of their interrelationship.
Berkowitz FE. Reviews of Infectious Diseases. 1991;13:1151-1162.
Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causes nonspherocytic hemolytic anemia.
Wang C, Chiarelli LR, Bianchi P, Abraham DJ. Blood. 2001;98:3113.
Hereditary elliptocytosis, spherocytosis and related disorders: consequences of a deficiency or a mutation of membrane skeletal proteins.
Palek J. Blood Rev. 1987;1:147-68.
Treatment
Stable in-vivo expression of glucose-6-phosphate-dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer.
Rovira A, DeAngioletti M, Camacho-Vanegas O, et al. Blood 2000;96:4111.
Reduced chronic hemolysis during high dose vitamin E administration in Mediterranean-type glucose-6-phosphate dehydrogenase deficiciency.
Corash L, Spielberg S, Bartsocas C, et al. N Eng J Med. 1980;303:416-420.
Review
Clinical manifestations of paroxysmal nocturnal hemoglobinuria: present state and future problems.
Rosse WF, Nishimura J. Intl J Hematology. 2003;77:113-120.
G6PD deficiency.
Beutler E. Blood. 1994;84:3613-3636.
11. METABOLIC ENZYME DEFICIENCY HEMOLYTIC ANEMIAS AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Enzyme Deficiencies
Pathophysiology
Enzymatic deficiency in primaquine-sensitive erythrocytes
Carson PE, Flanagan CL, Ickes CE, Alving AS. Science. 1956;124:484-485.
A specific erythrocyte glycolytic enzyme defect (pyruvate kinase) in three subjects with congenital non-spherocytic hemolytic anemia.
Valentine WN, Tanaka KR, Miwa S. Trans Assoc Am Physicians. 1961;74:100-110.
Molecular heterogeneity of glucose-6-phosphate dehydrogenase A-.
Beutler E, Kuhl W, Vives-Corrons J-L, Prchal JT. Blood. 1989;74:2550-2555.
Glucose-6-phosphate dehydrogenase deficiency and malaria.
Ruwende C, Hill A. J Mol Med. 1998;76:581-588.
Genetic basis of hemolytic anemia caused by pyrimidine 5' nucleotidase deficiency.
Marinaki AM, Escuredo E, Duley JA, et al. Blood. 2001;97:3327-3332.
Review
G6PD deficiency.
Beutler E. Blood. 1994;84:3613-3636.
Biochemical and genetic basis of red cell enzyme deficiencies.
Jacobasch G. Baillieres Best Pract Res Clin Haematol. 2000;13:1-20.
Red cell pyruvate kinase deficiency: from genetics to clinical manifestations.
Zanella A, Bianchi P. Baillieres Best Pract Res Clin Haematol. 2000;13:57- 81.
Paroxysmal nocturnal hemoglobinuria
Pathogenesis
Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence.
Ware RE, Hall SE, Rosse WF. N Engl J Med. 1991;325:991-996.
Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria.
Takeda J, Miyata T, Kawagoe K, et al. Cell. 1993;73:703-711.
Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P, Bessler M, Mason PJ, Watkins WM, Luzzatto L. Proc Natl Acad Sci U S A. 1993;90:5272-5276.
The molecular basis of paroxysmal nocturnal hemoglobinuria.
Rosse WF, Ware RE. Blood. 1995;86:3277-3286.
Natural history of paroxysmal nocturnal hemoglobinuria.
Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. N Engl J Med. 1995;333:1253-1258.
The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot.
Mortazavi Y, Merk B, McIntosh J, Marsh JCW, Schrezenmeier H, Rutherford TR, for the BIOMED II Pathophysiology and Treatment of Aplastic Anaemia Study Group. Blood. 2003;101:2833-2841.
Molecular genetics of paroxysmal nocturnal hemoglobinuria.
Inoue N, Murakami Y, Kinoshita T. Int J Hematol. 2003;77:107-112.
Diagnosis
Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes.
Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Ann Intern Med. 1999;131:401-408.
Treatment
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P, Hall C, Marsh JCW, et al. N Engl J Med. 2004;350:552-559.
Review
Paroxysmal nocturnal hemoglobinuria as a molecular disease.
Rosse WF. Medicine (Baltimore). 1997;76:63-93.
12. SIDEROBLASTIC ANEMIA
Pathophysiology
A severe type of hereditary anemia with elliptocytosis. Interesting sequence of splenectomy.
Cooley TB. Am J Med Sci. 1945;209:561-568.
Chronic refractory anemia with sideroblastic bone marrow: a study of four cases.
Bjorkman SE. Blood. 1956;11:250-259.
Pyridoxine-responsive sideroblastic anemia due to antituberculous drugs.
Haden HT. Arch Intern Med. 1967;120:602.
Ferrokinetic abnormalities and their significance in patients with sideroblastic anemia.
Singh AK, Shinton NK, Williams JDF. Br J Haematol. 1970;18:67-77.
The evolution of anemia in alcoholic patients.
Eichner ER, Hillman RS. Am J Med. 1971;50:218-232.353.
A common progenitor for human myeloid and lymphoid cells.
Prchal JT, Throckmorton DW, Carroll 3 rd AJ, Fuson EW, Gams RA, Prchal JF. Nature. 1978;274:590-591.
Hereditary sideroblastic anemia in four siblings of a Libyan family: autosomal inheritance.
Kasturi J, Basha HM, Smeda SH, Swehil M. Acta Haematol. 1982;68:321-324.
Molecular defects of erythroid 5-aminolevulinate synthase in X-linked sideroblastic anemia.
Bottomley SS, May BK, Cox TC, Cotter PD, Bishop DF. J Bioenerg Biomembr. 1995;27:161-168.
From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndrome.
Gattermann N. Leuk Res. 1999;24:141-151.
Increased apoptosis in acquired sideroblastic anemia.
Matthes TW, Meyer G, Samii K, Beris P. Br J Haematol. 2000;111:843-852.
Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation.
Bekri S, Kispal G, Lange H, et al. Blood. 2000;96:3256-3264.
A human mitochondrial ferritin encoded by an intronless gene.
Levi S, Corsi B, Bosisio M, et al. J Biol Chem. 2001;276:24437-24440.
Description: Describes a novel mitochondrial ferritin that accumulates in erythroblast mitochondria in sideroblastic anemia.
CNS demyelination associated with copper deficiency and hyperzincemia.
Prodan CI, Holland NR, Wisdom PJ, Burstein SA, Bottomley SS.Neurology. 2002;59:1453-1456.
Diagnosis
A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction.
Pearson HA, Lobel JS, Kocoshis SA, et al. J Pediatr. 1979;95:976–984.
Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction.
Germing U, Gattermann N, Aivado M, Hildebrandt B, Aul C. Br J Haematol. 2000;108:724-728.
Review
The genetics of inherited sideroblastic anemias.
Fleming MD. Semin Hematol. 2002;39:270-281.
Secondary iron overload disorders.
Bottomley SS. Semin Hematol. 1998;35:77-86.
13. PORPHYRIAS
Pathophysiology
Hemochromatosis genes and other factors contributing to the pathogenesis porphyria cutanea tarda.
Bulaj ZJ, Phillips JD, Ajioka RS, et al. Blood. 2000;95:1565-1571.
Diagnosis
ACP Best Practice No 165: front line tests for the investigation of suspected porphyria.
Deacon AC, Elder GH. J Clin Pathol. 2001;54:500-507.
Treatment
Acute porphyria: treatment with heme.
Tenhunen R, Mustajoki P. Semin Liver Dis. 1998;18:53-55.
Early administration of heme arginate for acute porphyric attacks.
Mustajoki P, Nordmann Y. Arch Intern Med. 1993;153:2004-2008.
Congenital erythropoietic porphyria successfully treated by allogeneic bone marrow transplantation.
Tezcan I, Xu W, Gurgey A, et al. Blood. 1998;92:4053-4058.
Review
Childhood porphyrias.
Ahmed I. Mayo Clin Proc. 2002;77:825-836.
The acute porphyries.
Elder GH, Hift RJ, Meissner PN. Lancet. 1997;349:1613-1617.
Erythropoietic and hepatic porphyrias.
Gross U, Hoffmann GF, Doss MO. J Inherit Metab Dis. 2000;23:641-661.
Diagnosis and management of porphyria.
Thadani H, Deacon A, Peters T. BMJ. 2000;320:1647-1651.
14. HEMOCHROMATOSIS
Diagnosis
Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101168 participants in the hemochromatosis and iron overload screening (HEIRS) study.
Adams PC, Reboussin DM, Leiendecker-Foster C, et al. Clin Chem. 2005 Apr 15;
Hemochromatosis and iron-overload screening in a racially diverse population.
Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and Iron Overload Screening (HEIRS) Study research investigators. N Engl J Med. 2005;352:1769-1778.
Hemochromatosis mutations in the general population: iron overload progression rate
Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Blood. 2004;103:2914-2919.
Pathophysiology
Pathogenesis of hereditary hemochromatosis.
Fleming RE, Britton RS, Waheed A, Sly WS, Bacon BR. Clin Liver Dis. 2004;8:755-773.
Redox active plasma iron in C282Y/C282Y hemochromatosis.
Le Lan C, Loreal O, Cohen T, et al. Blood. 2005;105:4527-4531.
A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis.
Feder JN, Gnirke A, Thomas W, et al. Nature Genetics. 1996;13:399-408.
HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis.
Mura C, Raguenes O, Ferec C. Blood. 1999;93:2501-2505.
Review
Hereditary hemochromatosis—a new look at an old disease.
Pietrangelo A. N Engl J Med. 2004;350:2383-2397.
Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention.
Harrison SA, Bacon BR.
Med Clin North Am. 2005;89:391-409.
EASL international consensus conference on haemochromatosis.
Adams P, Brissot P, Powell LW.
J Hepatol. 2000;33:485-504.
Neonatal hemochromatosis
Murray KF, Kowdley KV.
Pediatrics. 2001;108:960-964.
15. ERYTHROCYTOSIS AND POLYCYTHEMIA VERA
Pathophysiology
Bone-marrow responses in polycythemia vera.
Prchal JF, Axelrad AA. N Engl J Med. 1974; 290:1382.
Polycythemia vera: stem-cell and probable clonal origin of the disease.
Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. N Engl J Med. 1976; 295:913-916.
A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course.
Swolin B, Weinfeld A, Westin J. Blood. 1988;72:386-395.
Diagnosis
Inapparent polycythemia vera: an unrecognized diagnosis.
Lamy T, Devillers A, Bernard M, et al. Am J Med. 1997;102:14-20.
Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.
Moliterno AR, Hankins WD, Spivak JL. N Engl J Med. 1998; 338:572-580
Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin.
Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Josef T. Prchal JT. Blood. 2003;101:3294-3301.
Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis.
Klippel S, Strunck E, Temerinac S, et al. Blood. 2003;102:3569-3574.
Treatment
Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia.
Pearson TC, Wetherley-Mein G. Lancet. 1978;312:1219-1222.
Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.
Berk PD, Goldberg JD, Silverstein MN, et al. N Engl J Med. 1981;304:441-447.
European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators: efficacy and safety of low-dose aspirin in polycythemia vera.
Landolfi R, Marchioli R, Kutti J, et al, for the European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. N Engl J Med. 2004;350:114-124.
Angiotensin-converting enzyme inhibitors for secondary erythrocytosis.
Fakhouri F, Grunfeld J-P, Hermine O, Delarue R. Ann Intern Med. 2004;140:492-493.
Review
Polycythemia: mechanisms and management.
Golde DW, Hocking WG, Koeffler HP, Adamson JW. Ann Intern Med. 1981;95:71-87.
Polycythemia vera: myths, mechanisms, and management.
Spivak JL. Blood. 2002;100:4272-4290.
Congenital and inherited polycythemia.
Kralovics R, Prchal JT. Curr Opin Pediatr. 2000;12:29-34.
16. GRANULOCYTE DYSFUNCTION DISORDER AND GRANULOCYTOPENIA
Granulocytopenia (neutropenia)
ACQUIRED
Idiopathic, immune, infectious, and idiosyncratic neutropenias
Palmblad J, von dem Borne AE. Semin Hematol. 2002;39:113-120.
A diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases.
Bux J, Behrens G, Jaeger G, Welte K. Blood. 1998;91:181-186.
Drugs in the aetiology of agranulocytosis and aplastic anaemia
Kaufman DW, Kelly JP, Jurgelon JM, et al. Eur J Haematol. 1996;60:23-30.
Hematopoietic growth factors in the older cancer patient
Balducci L, Hardy CL, Lyman GH. Curr Opin Hematol. 2001;8:170-187.
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines: American Society of Clinical Oncology Growth Factors Expert Panel.
Ozer H, Armitage JO, Bennett CL; American Society of Clinical Oncology. J Clin Oncol. 2000;18:3558-3585.
CONGENITAL
Cyclic neutropenia
Dale DC, Bolyard AA, Aprikyan AG. Semin Hematol. 2002;39:89-94.
SEVERE CONGENITAL NEUTROPENIA (KOSTMANN SYNDROME)
Infantile genetic agranulocytosis; agranulocytosis infantilis hereditaria
Kostmann R. Acta Paediatr 1956;45:1-78.
Kostmann syndrome and severe congenital neutropenia
Zeidler C, Welte K. Semin Hematol. 2002;39:82-88.
Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia
Dale DC, Person RE, Bolyard AA, et al. Blood. 2000;96:2317-2322.
Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry
Dale DC, Cottle TE, Fier CJ, et al. Am J Hematol. 2003;72:82-93.
Hematopoietic stem cell transplantation in severe congenital neutropenia: experience of the French SCN register
Ferry C, Ouachee M, Leblanc T, et al. Bone Marrow Transplant. 2005;35:45-50.
OTHER CONGENITAL NEUTROPENIAS
Congenital neutropenia.
Ancliff PJ. Blood Rev. 2003;17:209-216.
Granulocyte Dysfunction
CHRONIC GRANULOMATOUS DISEASE (CGD)
A fatal granulomatosis of childhood: the clinical, pathological, and laboratory features of a new syndrome.
Bridges RA, Berendes H, Good RA. AMA J Dis Child. 1959;97:387-408.
Leukocyte oxidase: defective activity in chronic granulomatous disease.
Baehner RL, Nathan DG. Science. 1967;155:835-836.
Chronic granulomatous disease: report on a national registry of 368 patients.
Winklestein JA, Marino MC, Johnston Jr RB, et al. Medicine. 2000;79:155-169.
Hematologically important mutations: X-linked chronic granulomatous disease (second update).
Heyworth PG, Curnutte JT, Rae J, et al. Blood Cells Mol Dis. 2001;27:16-26.
Current treatment options for chronic granulomatous disease.
Goldblatt D. Expert Opin Pharmacother. 2002;3:857-863.
Characterization of six novel mutations in the CYBB gene leading to different sub-types of X-linked chronic granulomatous disease.
Stasia MJ, Bordigoni P, Floret D, et al. Hum Genet. 2005;116:72-82.
LEUKOCYTE ADHESION DEFICIENCY
Leukocyte adhesion deficiency: An inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins.
Anderson DC , Springer TA. Annu Rev Med. 1987;38:175-194.
The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter.
Luhn K, Wild MK, Eckhardt M, Gerardy-Schahn R, Vestweber D. Nat Genet 2001;28:69-72.
Correction of leukocyte adhesion deficiency type II with oral fucose.
Marquardt T, Luhn K, Srikrishna G. Blood. 1999;94:3976-3985.
MYELOPEROXIDASE (MPO) DEFICIENCY
Clinical manifestation of myeloperoxidase deficiency.
Lanza F. J Mol Med. 1998;76:676-681.
Molecular genetics of peroxidase deficiency.
Petrides PE . J Mol Med. 1998;76:688-698.
HYPERIMMUNOGLOBULIN E SYNDROME
Hyper-IgE syndrome with recurrent infections: an autosomal dominant multisystem disorder.
Grimbacher B, Holland SM, Gallin JI, et al. N Engl J Med. 1999;340:692-702.
OTHER GRANULOCYTE DYSFUNCTION DISORDERS
Immunodeficiency diseases caused by defects in phagocytes.
Lekstrom-Himes JA, Gallin JI. N Engl J Med. 2000;343:1703-1714.
17. FEBRILE NEUTROPENIA
Disease Pathophysiology
The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
Klastersky J, Paesmans M, Rubenstein EB, et al. J Clin Oncol. 2000;18:3038-3051.
Treatment
Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients: a systematic review of the literature with meta-analysis.
Berghmans T, Paesmans M, Lafitte JJ, et al. Support Care Cancer. 2002;10:181-188.
Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
Crawford J. Semin Oncol. 2003;30:24-30.
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.
Hughes WT, Armstrong D, Bodey GP, et al. Clin Infect Dis. 2002;34:730-751.
A prospective randomized evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia.
Lalami Y, Paesmans M, Aoun M, et al. Support Care Cancer. 2004;12:725-730.
Evolving concepts of management of febrile neutropenia in children with cancer.
Orudjev E, Lange BJ. Med Pediatr Oncol. 2002;39:77-85.
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
Ozer H, Armitage JO, Bennett CL, et al. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000;18:3558-3585.
Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients.
Vidal L, Paul M, Ben-Dor I, Pokroy E, Soares-Weiser K, Leibovici L. Cochrane Database Syst Rev. 2004:CD003992.
Empirical antifungal therapy in treating febrile neutropenic patients.
Wingard JR. Clin Infect Dis. 2004;39:S38-S43.
Systemic antifungal therapy: new options, new challenges.
Wong-Beringer A, Kriengkauykiat J. Pharmacotherapy. 2003;23:1441-1462.
Review
Congenital neutropenia: advances in diagnosis and treatment.
Badolato R, Fontana S, Notarangelo LD, Savoldi G. Curr Opin Allergy Clin Immunol. 2004;4:513-521.
Febrile neutropenia: past, present and future.
Neth O, Klein N. Adv Exp Med Biol. 2004;549:119-124.
Fever in immunocompromised patients.
Pizzo PA. N Engl J Med. 1999;341:893-900.
Perspectives for the management of febrile neutropenic patients with cancer in the 21st century.
Sipsas NV, Bodey GP, Kontoyiannis DP. Cancer. 2005;103:1103-1113.
18. LYMPHOPENIA AND LYMPHOCYTE DISORDERS
Diagnosis and Pathophysiology
Atypical cellular disorders.
McClain KL, Natkunam Y, Swerdlow SH. Hematology (Am Soc Hematol Educ Program). 2004:283-296.
Congenital and acquired neutropenia.
Berliner N, Horwitz M, Loughran TP Jr. Hematology (Am Soc Hematol Educ Program). 2004:63-79.
T cell dynamics in HIV-1 infection.
Douek DC, Picker LJ, Koup RA. Annu Rev Immunol. 2003;21:265-304.
Homeostasis and T cell regulation.
Stockinger B, Kassiotis G, Bourgeois C. Curr Opin Immunol. 2004;16:775-779.
Hematological findings in SARS patients and possible mechanisms.
Yang M, Li CK, Li K, et al. Int J Mol Med. 2004;14:311-315.
The Wiskott-Aldrich syndrome.
Ochs HD. Semin Hematol. 1998;35:332-345.
WASp in immune system organization and function.
Thrasher AJ. Nat Rev Immunol. 2002;2:635-646.
Severe combined immunodeficiency: a model disease for molecular immunology and therapy.
Fischer A, Le Deist F, Hacein-Bey-Abina S, et al. Immunol Rev. 2005;203:98-109.
Cytokines and immunodeficiency diseases.
Leonard WJ. Nat Rev Immunol. 2001;1:200-208.
Treatment
Unrelated donor bone marrow transplantation for correction of lethal congenital immunodeficiencies.
Filipovich AH, Shapiro RS, Ramsay NK, et al. Blood. 1992;80:270-276.
Umbilical cord blood transplantation in severe T-cell immunodeficiency disorders: two-year experience.
Knutsen AP, Wall DA. J Clin Immunol. 2000;20:466-476.
Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.
Buckley RH, Schiff SE, Schiff RI, et al. N Engl J Med. 1999;340:508-516.
Review
Primary immunodeficiency diseases.
Bonilla FA, Geha RS. J Alleg Clin Immunol. 2003;111:S571-S581.
The mechanisms of immune diversification and their disorders.
De Villartay JP, Fischer A, Durandy A. Nat Rev Immunol. 2003;3:962-972.
A historical review of bone marrow transplantation for immunodeficiencies.
Buckley RH. J Allergy Clin Immunol. 2004;113:793-800.
Primary immunodeficiency disorders: antibody deficiency.
Ballow M. J Allerg Clin Immunol. 2002;109:581-591.
19. ESSENTIAL THROMBOCYTHEMIA AND SECONDARY THROMBOCYTOSIS
Pathophysiology/etiology
Thrombocytosis in adults: analysis of 777 patients.
Santhosh-Kumar CR, Yohannan MD, Higgy KE, al- Mashhadani SA. J Intern Med. 1991;229:493-495.
Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell.
Fialkow PJ, Faguet GB, Jacobson RJ, et al. Blood. 1981;58:916-919.
Diagnosis
Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.
Murphy S, Peterson P, Iland H, Laszlo J. Semin Hematol. 1997;34:29-39.
Treatment
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.
Cortelazzo S, Finazzi G, Ruggeri M, et al. New Engl J Med. 1995;332:1132-1136.
Interferon-alpha in the treatment of essential thrombocythaemia.
Lengfelder E, Griesshammer M, Hehlmann R. Leuk Lymphoma. 1996;22:135-142.
No treatment for low-risk thrombocythaemia: results from a prospective study.
Ruggeri M, Finazzi G, Tosetto A, et al. Br J Haematol. 1998;103:772-777.
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
Finazzi G, Ruggeri M, Rodeghiero F, et al. Br J Haematol. 2000;110:577-583.
Long-term use of anagrelide in young patients with essential thrombocythemia.
Storen EC, Tefferi A. Blood. 2001;97:863-866.
A single institutional experience with 43 pregnancies in essential thrombocythemia.
Wright CA , Tefferi A. Eur J Haematol. 2001;66:152-159.
Review
Essential thrombocythemia.
Harrison CN, Green AR. Hematol Oncol Clin N Am. 2003;17:1175-1190.
Thrombocytosis.
Schafer, AI. New Engl J Med. 2004;350:1211-1219.
20. APLASTIC ANEMIA
Pathophysiology
Progressive telomere shortening in aplastic anemia.
Ball SE, Gibson FM, Rizzo S, et al. Blood. 1998;91:3582-3592.
Antithymocyte globulin with or without cyclosporine A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.
Frickhofen N, Heimpel H, Kaltwasser JP, et al. Blood. 2003;101:1236-1242.
Haemopoietic growth factor production by normal and aplastic anaemia stroma in long-term bone marrow culture.
Gibson FM, Scopes J, Daly S, et al. Br J Haematol. 1995;91:551-561.
Increased frequencies of glutathione S-transferase (GSTMI and GSTTI) gene deletions in Korean patients with acquired aplastic anemia.
Lee KA, Kim SH, Woo HY, et al. Blood. 2001;98:3483-3485.
Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia.
Sloand E, Kim S, Maciejewski JP, et al. Blood. 2002;100:1185-1191.
Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (CY): follow-up of a randomized trial.
Tisdale JT, Maciejewski JP, Nunez O, et al. Blood. 2002;100:4668-4670.
Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia
Yamaguchi H, Calado RT, Ly H, et al. N Engl J Med. 2005;352:1413-1424.
Diagnosis
Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA.
Fogarty PF, Yamaguchi H, Wiestner A, et al. Lancet. 2003;362:1628-1630.
Treatment
Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy—The European Group for Blood and Marrow Transplantation experience.
Bacigalupo A, Brand R, Oneto R, et al. Semin Hematol. 2000;37:69-80.
Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony – stimulating factor for severe aplastic anemia: an update of the GITMO/EVMT study on 100 patients.
Bacigalupo A, Bruno B, Saracco P, et al. Blood. 2000;95:1931-1934.
Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation.
Brodsky RA, Sensenbrenner LL, Jones RJ. Blood. 1996;87:491-494.
Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy.
Doney K, Leisenring W, Storb R, et al. Ann Intern Med. 1997;126:107-115.
Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine: the German Aplastic Anemia Study Group.
Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. N Engl J Med. 1991;324:1297-1304.
Long term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation.
Kojima S, Horibe K, Inaba J, et al. Br J Haematol. 2000;111:321-328.
Treatment with marrow transplantation or immunosuppression of childhood acquired severe aplastic anemia: a report from the EBMT SAA Working Party.
Locasciulli A, van’t Veer L, Bacigalupo A, et al. Bone Marrow Transplant. 1990;6:211-217.
Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporine for treatment of patients with nonsevere aplastic anemia: a report from the European Blood an Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party.
Marsh J, Schrezenmeier H, Marin P, et al. Blood. 1999;93:2191-2195.
Bone marrow transplantation for severe aplastic anemia: has outcome improved?
Passweg JR, Socie G, Henterberger W, et al. Blood. 1997;90:858-864.
Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia.
Rosenfeld SJ, Kimball J, Vining D, et al. Blood. 1995;85:3058-3065.
Review
The pathophysiology of acquired aplastic anemia.
Young NS, Maciejewski J. N Engl J Med. 1997;336:1365-1372.
Aplastic anaemia.
Brodsky RA, Jones RJ. Lancet. 2005;365:1647-1656.
21. NORMAL MECHANISMS OF HEMOSTASIS
Diagnosis and Pathophysiology
Waterfall sequence for intrinsic blood clotting.
Davie EW, Ratnoff OD. Science. 1964;145:1310-1312.
An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier.
Macfarlane RG. Nature. 1964;202:498-499.
Activation of factor IX by the reaction product of tissue factor and factor VII.
Østerud B, Rapaport S. Proc Natl Acad Sci U S A. 1977;74:5260-5264.
Exposure of platelet fibrinogen receptors by ADP and epinephrine.
Bennett JS, Vilaire G. J Clin Invest. 1979;64:1393-1401.
Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium.
Sakariassen KS, Bolhuis PA, Sixma JJ.Nature. 1979;279:636-638.
Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody.
Bennett JS, Hoxie JA, Leitman SF, Leitman SF, Vilaire G, Cines DB. Proc Natl Acad Sci U S A. 1983;80:2417-2421.
Factor XI activation in a revised model of blood coagulation.
Gailani D, Broze GJ. Science. 1991;253:909-912.
Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation.
Hoffman M, Monroe DM, Oliver JA, Roberts HR. Blood. 1995;86:1794-1801.
Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor.
Savage B, Saldivar E, Ruggeri ZM. Cell. 1996;84:289-297.
ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.
Dong JF, Moake JL, Nolasco L, et al. Blood. 2002;100:4033-4039.
Role of P-selectin and PSGL-1 in coagulation and thrombosis.
Vandendries ER, Furie BC, Furie B. Thromb Haemost. 2004;92:459-466.
Treatment
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Chest. 2004;126:401S-428S.
Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies.
Leone G, Rossi E, Leone AM, De Stefano V. Curr Med Chem Cardiovasc Hematol Agents. 2004;2:311-326.
Review
A brief historical review of the waterfall/cascade of blood coagulation.
Davie EW. J Biol Chem. 2003;278:50819-50832.
Von Willebrand factor, platelets and endothelial cell interactions.
Ruggeri, ZM. J Thromb Haemost. 2003;1:1335-1342.
Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases.
Dahlback B. J Intern Med. 2005;257:209-223.
Progress in the understanding of the protein C anticoagulant pathway.
Dahlback B. Int J Hematol. 2004;79:109-116.
Regulation of vascular bed-specific prothrombotic potential.
Edelberg JM, Christie PD, Rosenberg RD. Circ Res. 2001;89:117-124.
The blood coagulation cascade.
Schenone M, Furie BC, Furie B. Curr Opin Hematol. 2004;11:272-277.
Hemostasis during normal pregnancy and puerperium.
Hellgren M. Semin Thromb Hemost. 2003;29:125-130.
22. HYPERCOAGULABLE STATES
Pathophysiology
Genetic testing for thrombophilia mutations.
Hertzberg MS. Semin Thromb Hemost. 2005;31:33-38.
Elevated clotting factor levels and venous thrombosis.
Bertina RM. Pathophysiol Haemost Thromb. 2004;33:395-400.
Treatment
Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer.
Couban S, Goodyear M, Burnell M, et al. J Clin Oncol. 2005;Mar 14 [Epub ahead of print].
Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients.
Verso M, Agnelli G, Bertoglio S, et al. J Clin Oncol. 2005;23:4057-4062.
The randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators.
Lee AYY, Levine MN, Baker RI, et al. N Engl J Med. 2003;349:146-153.
Review
Management options for thrombophilias.
Gallus AS. Semin Thromb Hemost. 2005;31:118-126.
Venous thromboembolism and cancer: new issues for an old topic.
Mandala M, Ferretti G, Cremonesi M, Cazzaniga M, Curigliano G, Barni S. Crit Rev Oncol Hematol. 2003;48:65-80.
23. HEPARIN INDUCED THROMBOCYTOPENIA
Pathophysiology
Heparin-induced immune thrombocytopenia.
Babcock RB, Dumper CW, Scharfman WB. N Eng J Med. 295:237-241.
Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.
Visentin GP, Ford SE, Scott JP, Ashter RH. J Clin Invest. 1994;93:81-88.
Heparin-associated thrombocytopenia: isolation of the antibody and characterization of multimolecular PF-4-heparin complex as the major antigen.
Greinacher A, Potzsch B, Amiral J, Dummel V, Eichener A, Mueller-Eckhardt C. Thromb Haemost. 1994;71:247-251.
Temporal aspects of heparin-induced thrombocytopenia.
Warkentin TE, Kelton JG. N Eng J Med. 2001;344:1286-1292.
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.
Warkentin TE, Levine MN, Hirsh J, et al. N Eng J Med. 332:1330-1335.
A 14-year study of heparin-induced thrombocytopenia.
Warkentin TE, Kelton JG. Am J Med. 1996;101:502-507.
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin induced thrombocytopenia
Rauova L, Poncz M, McKenzie SE, et al. Blood. 2005;105:131-138.
The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes.
Gruel Y, Pouplard C, Lasne D, Magdelaine-Beuzelin C, Charroing C, Watier H. Blood. 2004;104:2791-2793.
Diagnosis
A diagnostic test for heparin-induced thrombocytopenia.
Sheridan D, Carter C, Kelton JG. Blood. 1986;67:27-30.
First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA.
Eichler P, Budde U, Haas S, et al. Thromb Haemost. 1999;81:625-629.
Treatment
Failure of early heparin cessation as treatment for heparin induced thrombocytopenia.
Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Am J Med. 1999;106:629-635.
A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.
Farner B, Eichler P, Kroll H, Greinacher A. Thromb Haemost. 2001;85:950-957.
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
Lewis BE, Wallis DE, Berkowtiz SD, et al. Circulation. 2001;103:1838-1843.
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: more results.
Mahaffey KW, Lewis BE, Wildermann NM, et al. J Invasive Cardiol. 2003;15:611-616.
Review
Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy.
Warkentin TE, Greinacher A. Chest. 2005;126:311s-337s.
24. HEREDITARY PLATELET DISORDERS AND ACQUIRED PLATELET FUNCTION DISORDERS
Pathophysiology
ACQUIRED PLATELET DYSFUNCTION
Final report on the aspirin component of the ongoing Physicians' Health Study: Steering Committee of the Physicians' Health Study Research Group.
N Engl J Med. 1989; 321:129-135.
Bleeding complications associated with cardiopulmonary bypass.
Woodman RC, Harker LA. Blood. 1990;76:1680-1697.
Congenital Platelet Dysfunction
ADHESION
Bernard-Soulier Syndrome.
López JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Blood. 1998;91:4397-4418.
AGGREGATION
Glanzmann's thrombasthenia: the spectrum of clinical disease.
George JN, Caen JP, Nurden AT. Blood. 1990;75:1383-1395.
SIGNALING/SECRETION
Heterogeneous defects of platelet secretion and responses to weak agonists in patients with bleeding disorders.
Weiss, HJ Lages B. Br J Haematol. 1988;68:53-62.
Positional cloning of a gene for Hermansky-Pudlak syndrome, a disorder of cytoplasmic organelles.
Oh J, Bailin T, Fukai K, et al. Nature Genet. 1996;14:300-306.
The Wiskott-Aldrich syndrome.
Ochs HD. Semin Hematol. 1998;35:332-345.
Newly recognized cellular abnormalities in the gray platelet syndrome.
Drouin A, Favier R, Massé J-M, et al. Blood. 2001;98:1382-1391.
Asp1424Asn MYH9 mutation results in an unstable protein responsible for the phenotypes in May-Hegglin anomaly/Fechtner syndrome.
Deutsch S, Rideau A, Bochaton-Piallat M-L, et al. Blood. 2003;102:529-534.
PROCOAGULANT ACTIVITY
Scott syndrome: a disorder of platelet coagulant activity.
Weiss HJ. Semin Hematol. 1994;31:312-319.
CONGENITAL THROMBOCYTOPENIC DISORDERS
Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production.
Geddis AE, Kaushansky K. Curr Opin Pediatr. 2004;16:15-22.
Diagnosis
A critical reappraisal of the bleeding time.
Channing Rodgers RP, Levin J. Semin Thromb Hemost. 1990;16:1-20.
Treatment
Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.
Mannucci PM. Blood. 1997;90:2515-2521.
Hemostatic drugs.
Mannucci PM. N Engl J Med. 1998;339:245-253.
Review
The clinical importance of acquired abnormalities of platelet function.
George JN, Shattil SJ. N Engl J Med. 1991;324:27-39.
Inherited defects of platelet function.
Nurden AT, Nurden P. Rev Clin Exp Hematol. 2001;5:314-334.
Inherited defects in platelet signaling mechanisms.
Koneti Rao A. J Thromb Haemost. 2003;1:671-681.
25. BLEEDING DISORDERS
Hemophilia A and B
PATHOPHYSIOLOGY
Christmas disease: a condition previously mistaken for haemophilia.
Biggs R, Douglas AS, Macfarlane RG, et al. Br Med J. 1952;2:1378-1382.
The role of phospholipids and Factor VIII in the activation of bovine Factor X.
van Dieijen G, Tans G, Rosing J, Hemker HC. J Biol Chem. 1981;256:3433.
Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation.
Hoffman M, Monroe DM, Oliver JA, Roberts HR. Blood. 1995;86:1794.
Characterization of the human factor VIII gene.
Gitschier J, Wood WI, Goralka TM, et al. Nature 1984;312:326-330.
Structure of human factor VIII.
Vehar GA, Keyt B, Eaton D, et al. Nature. 1984;312:337-342.
Inversions disrupting the factor VIII gene are a common cause of severe haemophilia.
Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier JA. Nat Genet. 1993;5(3):236-41.
Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions.
Naylor J, Brinke A, Hassock S, Green PM, Giannelli F. Hum Mol Genet. 1993;2:1773-1778.
DIAGNOSIS
Diagnostic symptoms of severe and moderate haemophilia A and B: a survey of 140 cases.
Ljung R, Petrini P, Nilsson IM. Acta Paediatr Scand. 1990;79:196-200.
TREATMENT
Recombinant clotting factors in the treatment of hemophilia.
Lee C. Thromb Haemost. 1999;82:516.
Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM. Semin Thromb Hemost. 2000;26:179-188.
Gene transfer as an approach to treating hemophilia.
High KA. Semin Thromb Hemost 2003;29:107-120.
REVIEW
Congenital hemorrhagic disorders: new insights into the pathophysiology and treatment of hemophilia.
Hedner U, Ginsburg D, Lusher JM, High KA. Hematology (Am Soc Hematol Educ Program). 2000;241- 265.
Congenital bleeding disorders.
Rick ME, Walsh CE, Key NS. Hematology (Am Soc Hematol Educ Program). 2003:559- 574.
von Willebrand Disease
DIAGNOSIS
The effect of ABO blood group on the diagnosis of von Willebrand disease.
Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. Blood. 1987;69:1691-1695.
A revised classification of von Willebrand disease: for the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
Sadler JE. Thromb Haemost. 1994;71:520-525.
Von Willebrand disease type 1: a diagnosis in search of a disease.
Sadler JE. Blood. 2003;101:2089-2093.
TREATMENT
Treatment of von Willebrand's Disease.
Mannucci PM. N Engl J Med. 2004;351:683-694.
REVIEW
Impact, diagnosis, and treatment of von Willebrand disease.
Rare Inherited Bleeding Disorders
Recessively inherited coagulation disorders.
Mannucci PM, Duga S, Peyvandi F. Blood. 2004;104:1243-1252.
Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter.
Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownlee GG. Science. 1992;257:377-379.
Acquired Bleeding Disorders
Acquired von Willebrand syndrome: from pathophysiology to management.
Veyradier A, Jenkins CS, Fressinaud E, Meyer D. Thromb Haemost. 2000;84:175-182.
Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.
Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Br J Haematol. 2003;121:21-35.
26. ANTIPHOSPHOLIPID ANTIBODY SYNDROME
Diagnosis
Clinical laboratory testing for the antiphospholipid antibody syndrome.
Pierangeli SS, Harris EN. Clin Chim Acta. 2005;May 10 [Epub ahead of print].
Validation of the preliminary criteria for the classification of catastrophic antiphospholipid antibody syndrome
Cervera R, Font J, Gomez-Puerta JA, et al. Ann Rheum Dis. 2005;Feb 11 [Epub ahead of print].
Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests
Galli M, Barbui T. Semin Thromb Hemost. 2005;31:17-24.
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.
Cervera R, Piette JC, Font J, et al. Arthritis Rheum. 2002;46:1019-1027.
Pathophysiology
Genetics of antiphospholipid syndrome.
Horita T, Merrill JT. Curr Rheumatol Rep. 2004;6:458-462.
Molecular pathogenesis of the antiphospholipid antibody syndrome.
Rand JH. Circ Res. 2002;90:29-37.
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with antiphospholipid antibody syndrome.
Rand JH, Wu XX, Lapinski R, et al. Blood. 2004;104:2783-2790.
Treatment
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.
Crowther MA, Ginsberg JS, Julian J, et al. N Engl J Med. 2003;349:1133-1138.
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).
G. Finazzi G, R. Marchioli R, V. Brancaccio V, et al. J Thromb Haemost. 2005;3:848-853.
Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies.
Triolo G, Ferrante A, Ciccia F, et al. Arthritis Rheum. 2003;48:728-731.
Treatment of the antiphospholipid antibody syndrome.
Wu C, Kalunian K. Curr Rheumatol Rep. 2004;6:463-468.
Review
The antiphospholipid antibody syndrome.
Rand JH. Annu Rev Med. 2003;54:409-424.
Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations.
Avcin T, Cimaz R, Meroni PL. Lupus. 2002;11:4-10.
Update on the management of the pregnant patient with antiphospholipid antibody.
Sammaritano LR. Curr Rheumatol Rep. 2001;3:213-321.
27. PHARMACOLOGIC MANIPULATION OF BLEEDING AND THROMBOSIS
Treatment
Ximelagatran vs. low-molecular-weight heparin and warfarin for the treatment of deep venous thrombosis: a randomized trial.
Fiessinger JN, Huisman MV, Davidson BL, et al. JAMA. 2005;293:681-689.
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
Buller HR, Davidson BL, Decousus H, et al; Matisse investigators. N Engl J Med. 2003;349:1695-1702.
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Buller HR, Davidson BL, Decousus H, et al; Matisse investigators. Ann Intern Med. 2004;140:867-873.
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a Phase II evaluation.
Buller HR, Cohen AT, Lensing AWA, et al. J Thromb Haemost. 2004;2:47-53.
Review
A pharmacologic overview of current and emerging anticoagulants.
Nutescu EA, Shapiro NL, Chevalier A, Amin AN. Cleve Clin J Med. 2005;72:S2-S6.
New anticoagulants.
Hirsh J, O’Donnell M, Weitz JI. Blood. 2005;105:453-463.
Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review.
Levi M, Peters M, Buller HR. Crit Care Med. 2005;33:883-890.
The use of vitamin K in patients on anticoagulant therapy: a practical guide.
Hanslik T, Prinseau J. Am J Cardiovasc Drugs. 2004;4:43-55.
28. DISSEMINATED INTRAVASCULAR COAGULATION
Pathophysiology
Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice.
Levi M, Dorffler-Melly J, Reitsma P, Buller H, Florquin S, van der Poll T, Carmeliet P. Blood. 2003;101:4823-4827.
Advances in the understanding of pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies.
Levi M, de Jonge E, van der Poll T, ten Cate H. Semin Thromb Hemost. 2001;27:569-575.
Diagnosis
Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases.
Siegal T, Seligsohn U, Aghai E, Modan M. Thromb Haemost. 1978;39:122.
Screening tests of disseminated intravascular coagulation: guidelines for rapid and specific laboratory diagnosis.
Yu M, Nardella A, Pechet L. Crit Care Med. 2000;28:1777-1780.
Diagnosis of disseminated intravascular coagulation: role of D-dimer.
Carr JM, McKinney M, McDonagh J. Am J Clin Pathol. 1989;91:280-287.
Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compare patterns of antithrombin III, protein C, and protein S deficiencies.
Fourrier F, Chopin C, Goudemand J, et al. Chest .1992;101:816-823.
Treatment
Treatment of disseminated intravascular coagulation.
Feinstein, DI. Semin Thromb Haem. 1998;14:351-362.
Disseminated intravascular coagulation and sustained systemic inflammatory response syndrome predict organ dysfunctions after trauma: application of clinical decision analysis.
Gando S, Nanzaki S, Kemmotsu O. Ann Surg. 1999;229:121-127.
Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR, Vincent JL, Laterre PF, et al. N Engl J Med. 2001;344:699-709.
Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.
Warren BL, Eid A, Singer P, et al. JAMA. 2001;286:1869-1878.
Review
Disseminated intravascular coagulation.
Levi M, Cate HT. N Engl J Med. 1999;341:586-592.
Disseminated intravascular coagulation: old disease, new hope.
Toh CH, Dennis M. BMJ. 2003;327:4823-4827.
29. CHRONIC MYELOID LEUKEMIA
Pathophysiology
A minute chromosome in human chronic granulocytic leukemia.
Nowell PC, Hungerford DA. Science. 1960;132:1497.
Induction of chronic myelogenous leukemia in mice by the p210 BCR/ABL gene of the Philadelphia chromosome.
Daley GQ, Van Etten RA, Baltimore D. Science.1990;247:824-830.
Treatment
Bone marrow transplantation for patients with chronic myeloid leukemia.
Goldman JM, Apperley JF, Jones L, et al. N Engl J Med. 1986;314:202-207.
Bone marrow transplantation for chronic myeloid leukemia: long-term results: Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation.
Gratwohl A, Hermans J, Niederwieser D, et al. Bone Marrow Transplant. 1993;12:509-516.
Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia: The German CML Study Group.
Gale RP, Hehlmann R, Zhang M-J, et al. Blood. 1998;91:1810-1819.
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa.
Hasford J, Prirrmann M, Hehlmann R, et al. J Natl Cancer Inst. 1998;90:850-858.
Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.
Dazzi F, Szydlo RM, Goldman JM. Exp Hematol. 1999;27:1477-1486.
Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.
Weisdorf DJ, Anasetti C, Antin JH, et al. Blood. 2002;99:1971-1977.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
O’Brien SG, Guilhot F, Larson RA, et al. New Engl J Med. 2003;348:994-1004.
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Hughes TP, Kaeda J, Branford S, et al. New Engl J Med. 2003;349:1423-1432.
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate.
O’Dwyer ME, Mauro MJ, Blasdel C, et al. Blood. 2004;103:451-455.
Review
Interferon-alfa for chronic myeloid leukemia.
Baccarani M, Russo D, Rosti G and Marinelli G. Semin Hematol. 2003;40:22-33.
Chronic myeloid leukemia.
Melo JV, Hughes TP, Apperley JF. Hematology (Am Soc Hematol Educ Program). 2003:132-152.
Advanced-phase chronic myeloid leukemia.
Cortes J, Kantarjian H. Semin Hematol. 2003;40:79-86.
30. IDIOPATHIC MYELOFIBROSIS
Of Historical Interest
Androgens and erythropoiesis. Further evaluation of testosterone treatment of myelofibrosis.
Gardner FH, Nathan DG. N Engl J Med. 1966;274:420-426.
Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis.
Jacobson RJ, Salo A, Fialkow PJ. Blood. 1978;51:189-194.
Prognosis
Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.
Dupriez B, Morel P, Demory JL, et al. Blood. 1996;88:1013-1018.
Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines.
Barosi, G. J Clin Oncol. 1999;17:2954-2970.
Treatment
Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.
Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Blood. 2000;95:2226-2233.
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
Devine SM, Hoffman R, Verma A, et al. Blood. 2002;99:2255-2258.
Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Deeg HJ, Gooley TA, Flowers ME, et al. Blood. 2003;102:3912-3918.
A phase 2 trial of combination low dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
Mesa RA, Steensma DP, Pardanani A, et al. Blood. 2003;101:2534-2541.
Molecular Mechanisms of Disease
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Levine RL, Wadleigh M, Cools J, et al. Cancer Cell. 2005;7:387-397.
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
Baxter EJ, Scott LM, Campbell PJ, et al. Lancet. 2005;365:1054-1061.
A gain-of-function mutation of JAK2 in myeloproliferative disorders.
James C, Ugo V, Le Couedic JP, et al. N Engl J Med. 2005;352:1779-1790.
Review
Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
Tefferi, A. Semin Hematol. 2003;40:18-21.
Myelofibrosis with myeloid metaplasia.
Tefferi, A. N Engl J Med. 2000;342:1255-1265.
31. ACUTE MYELOID LEUKEMIA
Diagnosis
Prognostically useful gene-expression profiles in acute myeloid leukemia.
Valk PJ, Verhaak RG, Beijen MA, et al. N Engl J Med. 2004;350:1617-1628.
Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.
Marcucci G, Mrozek K, Bloomfield CD. Curr Opin Hematol. 2005;12:68-75.
Cytogenetics in acute leukemia.
Mrozek K, Heerema NA, Bloomfield CD. Blood Rev. 2004;18:115-136.
Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome.
Keating MJ, Smith TL, Kantarjian H, et al. Leukemia. 1988;2:403-412.
Pathophysiology
Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML.
Kakizuka A, Miller WH Jr, Umesono K, et al. Cell. 1991;66:663-674.
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study.
Leith CP, Kopecky KJ, Godwin J, et al.Blood. 1997;89:3323-3329.
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.
Thiede C, Steudel C, Mohr B, et al. Blood. 2002;99:4326-4335.
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.
Levis M, Murphy KM, Pham R, et al. Blood. 2005;106:673-680.
C-kit as a target in the treatment of acute myelogenous leukemia.
Advani AS. Curr Hematol Rep. 2005;4:51-58.
Treatment
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.
Rai KR, Holland JF, Glidewell OJ, et al. Blood. 1981;58:1203-1212.
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
Cassileth PA, Harrington DP, Appelbaum FR, et al. N Engl J Med. 1998;339:1649-1656.
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
Sievers EL, Larson RA, Stadtmauer EA, et al; Mylotarg Study Group. J Clin Oncol. 2001;19:3244-3254.
Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia.
Levis M. Curr Opin Hematol. 2005;12:55-61.
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.
Huang ME, Ye YC, Chen SR, et al. Blood. 1988;72:567-572.
A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: the European APL Group.
Fenaux P, Chastang C, Chevret S, et al. Blood. 1999;94:1192-1200.
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients.
Shen ZX, Chen GQ, Ni JH, et al. Blood. 1997;89:3354-3360.
Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia.
Sanz MA, Tallman MS, Lo-Coco F. Blood. 2005;105:3019-3025.
Review
Possibilities for tailored and targeted therapy in paediatric acute myeloid leukemia.
Zwaan CM, Kaspers GJ. Br J Haematol. 2004;127:264-279.
Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis.
Bleakley M, Lau L, Shaw PJ, Kaufman A. Bone Marrow Transplant. 2002;29:843-852.
Management of acute myeloid leukemia in elderly patients.
Hiddemann W, Kern W, Schoch C, et al. J Clin Oncol. 1999;17:3569-3576.
Acute myeloid leukemia.
Stone RM, O'Donnell MR, Sekeres MA. Hematology (Am Soc Hematol Educ Program). 2004:98-117.
Adult acute myeloid leukaemia.
Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Crit Rev Oncol Hematol. 2004;50:197-222.
Unanswered questions in acute myeloid leukaemia.
Ferrara F. Lancet Oncol. 2004;5:443-450.
32. MULTIPLE MYELOMA AND RELATED DISEASES
Pathophysiology
A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
Kyle RA, Therneau TM, Rajkumar SV, et al. N Engl J Med. 2002;346:564-569.
Multiple myeloma: evolving genetic events and host interactions.
Kuehl WM, Bergsagel PL. Nat Rev Cancer. 2002;2:175-187.
Advances in biology of multiple myeloma: clinical applications.
Hideshima T, Bergsagel PL, Kuehl WM, Anderson K. Blood. 2004;104:607-618.
Diagnosis
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorder: report of the International Myeloma Working Group.
International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
International staging system for multiple myeloma.
Greipp P, San Miguel J, Durie B, et al. J Clin Oncol. 2005;23:3412.
Treatment
Solitary plasmacytoma of bone and asymptomatic multiple myeloma.
Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Blood. 2000;96:2037-2044.
Treatment of multiple myeloma.
Bartogie B, Shaughnessy J, Tricot G, et al. Blood. 2004;103:20-32.
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.
Myeloma Trialists’ Collaborative Group. J Clin Oncol. 1998;16:3832-3842.
Single versus double autologous stem-cell transplantation for multiple myeloma.
Attal M, Harousseau JL, Facon T, et al: Intergroupe Francophone du Myelome. N Engl J Med. 2003;349:2495-2502.
Antitumor activity of thalidomide in refractory multiple myeloma.
Singhal S, Mehta J, Desikan R, et al. N Engl J Med. 1999;341:1565-1571.
A phase II study of bortezomib in relapsed, refractory myeloma.
Richardson P, Bartogie B, Berenson J, et al. N Engl J Med. 2003;348:2609-2617.
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
Berenson JR, Hillner BE, Kyle RA, et al. J Clin Oncol. 2002;20:3719-3736.
Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma.
Dammaco F, Castoldi G, Rodjer S. Br J Haem. 2001;113:172-179.
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
Jagannath S, Durie BG, Wof J, et al.Br J Haem. 2005;129:776.
Superiority of thalidomide and dexamethasone over Vincristin-Doxorubicin-Dexamethasone (VAD) in preparation for autologous stem cell transplantation in multiple myeloma.
Cavo M, Zamagni E, Tosi P, et al. Blood. 2005;106:35-39.
Review
POEMS syndrome: definitions and long-term outcome.
Dispenzieri A, Kyle RA, Lacy MQ, et al. Blood. 2003;101:2496-2506.
Multiple myeloma.
Kyle RA, Rajkumar SV. N Eng J Med. 2004;351:1860-1872.
33. AMYLOIDOSIS
Pathophysiology
The systemic amyloidoses: clearer understanding of molecular mechanisms offers hope for more effective therapies.
Merlini G, Westermark P. J Intern Med. 2004;255:159-178.
Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis.
Abraham RS, Ballman KV, Dispenzieri A, et al. Blood. 2005;105:794-803.
Diagnosis
Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement
Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Am J Cardiol. 2005;95:535-537.
Diagnostic performance of quantitative {kappa} and {lambda} free light chain assays in clinical practice.
Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Clin Chem. 2005;51:878-881.
Quantitative analysis of serum free light chains: a new marker for the diagnostic evaluation of primary systemic amyloidosis.
Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Am J Clin Pathol. 2003;119:274-278.
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis
Dispenzieri A, Gertz MA, Kyle RA, et al. J Clin Oncol. 2004;22:3751-3757.
Treatment
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
Palladini G, Perfetti V, Perlini S, et al. Blood. 2005;105:2949-2951.
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628
Dhodapkar MV, Hussein MA, Rasmussen E, et al: United States Intergroup Trial Southwest Oncology Group. Blood. 2004;104:3520-3526.
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
Lachmann HJ, Gallimore R, Gillmore D, et al. Br J Haematol. 2003;122:78-84.
Review
Guidelines on the diagnosis and management of AL amyloidosis.
Guidelines Working Group of UK Myeloma Forum: British Committee for Standards in Haematology, British Society for Haematology. Br J Haematol. 2004;125:681-700.
Amyloidosis and Waldenstrom’s macroglobulinemia
Gertz MA, Merlini G, Treon SP. Hematology (Am Soc Hematol Educ Program). (2004):257-282.
34. MASTOCYTOSIS
Pathophysiology
Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
Pullarkat VA, Bueso-Ramos C, et al. Am J Hematol. 2003;73:12-17.
Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene.
Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Blood. 2002;100:2:661-665.
Diagnosis
Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings.
Horny HP, Valent P. Leuk Res 2001;25:7:543-551.
Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Valent P, Horny HP, Escribano L, et al. Leuk Res. 2001;25:603-625.
Treatment
Imatinib for systemic mast-cell disease.
Pardanani A, Elliott M, Reeder T, et al. Lancet. 2003;362:535-536.
Cladribine therapy for systemic mastocytosis.
Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Blood. 2003;102:4270-4276.
Review
Systemic mastocytosis.
Akin C, Metcalfe DD. Annu Rev Med. 2004;55:419-432.
Diagnosis and treatment of systemic mastocytosis: state of the art.
Valent P, Akin C, Sperr WR, et al. Br J Haematol. 2003;122:695-717.
Mastocytosis: current concepts in diagnosis and treatment.
Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Ann Hematol. 2002;81:677-690.
35. HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS
Case Studies
Langerhans cell (eosinophilic) granulomatosis: a clinicopathologic study encompassing 50 years.
Lieberman PH, Jones CR, Steinman RM, et al. Am J Surg Pathol.1996;20:519-552.
True histiocytic lymphoma: a morphologic, immunohistochemical, and molecular genetic study of 13 cases.
Copie-Bergman C, Wotherspoon AC, Norton AJ, Diss TC, Isaacson P. Am J Surg Pathol. 1998;22:1386-1392.
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases.
Pileri SA, Grogan TM, Harris NL, et al. Histopathology. 2002;41:1-29.
Review
Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review.
Fonseca R, Yamakawa M, Nakamura S, et al. Am J Hematol. 1998;59:161-167.
Langerhans cell histiocytosis research: past, present, and future.
Nezelof C, Basset F. Hematol Oncol Clin North Am. 1998;12:385-406.
Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome.
Howarth DM, Gilchrist GS, Mullan BP, Wiseman GA, Edmonson JH, Schomberg PJ
Cancer. 1999;85:2278-2290.
Histiocytic and Dendritic Cell Proliferations.
Weiss LM. In: Knowles, DM, ed. Neoplastic Hematopathology, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:1815-1846.
36. HODGKIN’S DISEASE
Pathophysiology
The role of cytokines in classical Hodgkin lymphoma.
Skinnider BF, Mak TW. Blood. 2002;99:4283-4297.
Characteristics of Hodgkin's lymphoma after infectious mononucleosis.
Hjalgrim H, Askling J, Rostgaard K, et al. N Engl J Med. 2003;349:1324-1332.
Diagnosis/Staging
Report of the committee on Hodgkin’s Disease staging classification.
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Cancer Res. 1971;31:1860-1861.
FDG-PET in the clinical management of Hodgkin lymphoma.
Hutchings M, Eigtved AI, Specht L. Crit Rev Oncol Hematol. 2004;52:19-32.
Treatment
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
Canellos GP, Anderson JR, Propert KJ, et al. N Engl J Med. 1992;327:1478-1484.
Hodgkin's disease: complications of therapy and excess mortality.
Hoppe RT. Ann Oncol. 1997;8:115-118.
Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients: International Hodgkin's Disease Collaborative Group.
Specht L, Gray RG, Clarke MJ, Peto R. J Clin Oncol. 1998;16:830-843.
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Schmitz N, Pfistner B, Sextro M, et al. Lancet. 2002;359:2065-2071.
Involved-field radiotherapy for advanced Hodgkin's lymphoma.
Aleman BM, Raemaekers JM, Tirelli U, et al. N Engl J Med. 2003;348:2396-2406.
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
Diehl V, Franklin J, Pfreundschuh M, et al. N Engl J Med. 2003;348:2386-2395.
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s Lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group.
Engert A, Schiller P, Josting A, et al. J Clin Oncol. 2003;21:3601-3608.
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Meyer RM, Gospodarowicz MK, Connors JM, et al. J Clin Oncol. 2005;23:4634-4642.
Prognosis
A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease.
Hasenclever D, Diehl V. N Engl J Med. 1998;339:1506-1514.
Review
Hodgkin's lymphoma: evolving concepts with implications for practice.
Meyer RM, Ambinder RF, Stroobants S. Hematology (Am Soc Hematol Educ Program). 2004;184-202.
37. B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
Pathophysiology
Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence.
Robison LL, Bhatia S. Br J Haematol. 2003;122:345-359.
Acute lymphoblastic leukaemia in adults: immunological subtypes and clinical features at presentation.
van't Veer MB, van Putten WL, Verdonck LF, et al. Ann Hematol. 1993;66:277-282.
Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic leukemia: correlation of expression and clinical outcome at first disease recurrence.
Wu S, Gessner R, von Stackelberg A, Kirchner R, Henze G, Seeger K. Cancer. 2005;103:1054-1063.
Diagnosis
Molecular diagnostics on lymphoid malignancies.
Chan WC, Fu K. Arch Pathol Lab Med. 2004;128:1379-1384.
Molecular analysis of minimal residual disease in adult acute lymphoblastic leukemia.
Foroni L, Hoffbrand AV. Best Pract Res Clin Haematol. 2002;15:71-90.
Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994.
Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BA. Leukemia. 2000;14:2276-2285.
Lack of benefit of early detection of relapse after completion of therapy for acute lymphoblastic leukemia.
Rubnitz JE, Hijiya N, Zhou Y, Hancock ML, Rivera GK, Pui CH. Pediatr Blood Cancer. 2005;44:138-141.
Treatment
Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
Aviles A, Garcia EL, Fernandez R, Gonzalez JL, Neri N, Diaz-Maqueo JC. Ann Hematol. 2002;81:368-373.
CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials.
Clarke M, Gaynon P, Hann I, et al. J Clin Oncol. 2003;21:1798-1809.
Therapy of non-Hodgkin's lymphoma.
Coffey J, Hodgson DC, Gospodarowicz MK. Eur J Nucl Med Mol Imaging. 2003;30:S28-S36.
Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.
Gaynon PS, Trigg ME, Heerema NA, et al. Leukemia. 2000;14:2223-2233.
A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia.
Kimby E, Brandt L, Nygren P, Glimelius B. Acta Oncol. 2001;40:224-230.
The role of allogeneic transplantation in non-Hodgkin's lymphoma.
Peggs KS, Mackinnon S, Linch DC. Br J Haematol. 2005;128:153-168.
In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Styczynski J, Pieters R, Huismans DR, Schuurhuis GJ, Wysocki M, Veerman AJ. Br J Haematol. 2000;110:813-818.
Review
Adult Burkitt leukemia and lymphoma.
Blum KA, Lozanski G, Byrd JC. Blood. 2004;104:3009-3020.
38. FOLLICULAR LYMPHOMA
Pathophysiology
Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation.
Ngan BY, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML. N Engl J Med. 1988;318:1638-1644.
The natural history of initially untreated low-grade non-Hodgkin's lymphomas.
Horning SJ, Rosenberg SA. N Engl J Med. 1984;311:1471-1475.
Treatment
Is radiotherapy curative for stage I and II low-grade follicular lymphoma? results of a long-term follow-up study of patients treated at Stanford University.
Mac Manus MP, Hoppe RT. J Clin Oncol. 1996;14:1282-1290.
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
Czuczman MS, Grillo-Lopez AJ, White CA, et al. J Clin Oncol. 1999;17:268-276.
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
Kaminski MS, Zelenetz AD, Press OW, et al. J Clin Oncol. 2001;19:3918-3928.
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
McLaughlin P, Grillo-Lopez AJ, Link BK, et al. J Clin Oncol. 1998;16:2825-2833.
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.
van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Blood 2003;102:3521-3529.
Review
Clinicopathologic analysis of follicular lymphoma occurring in children.
Lorsbach RB, Shay-Seymore D, Moore J, et al. Blood. 2002;99:1959-1964.
Intensive therapies in follicular non-Hodgkin lymphomas.
Hunault-Berger M, Ifrah N, Solal-Celigny P. Blood. 2002;100:1141-1152.
Follicular lymphomas: a review of treatment modalities.
Soubeyran P, Debled M, Tchen N, et al. Crit Rev Oncol Hematol. 2000;35:13-32.
39. AGGRESSIVE NHL
Pathophysiology
World Health Organization classification of neoplastic diseases of the hematopietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting: Airlie House, Virginia, November 1997.
Harris NL, Jaffe ES, Diebold J, et al. J Clin Oncol. 1999;17:3835-3849.
A predictive model for aggressive non-Hodgkin’s lymphoma: the International Non-Hodgkin’s Lymphoma Prognostic Factors Project.
N Engl J Med. 1993;329:987-994.
Diffuse large B cell lymphoma outcome prediction by gene expression profiling and supervised machine learning.
Shipp MA, Ross KN, Tamayo P, et al.Nat Med. 2002;8:68-74.
Prediction of survival in diffuse large B-cell lymphoma based on the expression of six genes.
Lossos IS, Czerwinski DK, Alizadeh AA, et al. N Engl J Med. 2004;350:1828-2837.
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
Rosenwald A, Wright G, Chan WC, et al, for the Lymphoma/Leukemia Molecular Profiling Project. N Engl J Med. 2002;346:1937-1947.
Review
Primary mediastinal B cell lymphoma: a review of pathology and management.
Van Besien K, Kelta M, Bahaguna P. J Clin Oncol. 2001;19:1855-1864.
Management of Adult Aggressive Non-Hodgkin’s Lymphomas.
Bernard C, Dujols J-P, Mokhtari F, Norkowski J-L, Slawinski J-C, Schlaifer D.
Crit Rev Oncol Hematol. 2000;35:33-48.
Treatment
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high grade Non-Hodkin’s Lymphoma.
Miller TP, Dahlberg S, Cassady RJ, et al. N Engl J Med. 1998;339:21-26.
Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group Study 1484.
Horning SJ, Weller E, Kim K, et al. J Clin Oncol. 2004;22:3032-3038.
Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma.
Fisher RJ, Gaynor ER, Dahlberg S, et al. N Engl J Med. 1993;328:1002-1006.
CHOP chemotherapy plus rituximab compared to CHOP alone in elderly patients with diffuse large B-cell lymphoma.
Coiffier B, Lepage E, Briere J, et al. N Engl J Med. 2002;346:235-242.
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Haioun C, Lepage E, Gisselbrecht C, et al. J Clin Oncol. 2000;18:3025-3030.
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive Non-Hodgkin’s lymphoma.
Philip T, Guglielmi C, Hagenbeek A, et al. N Engl J Med. 1995;333:1540-1545.
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
Kewalramani T, Zelenetz AD, Hedrick EE, et al. Blood. 2000;96:2399-2404.
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Kewalramani T, Zelenetz AD, Nimer SD, et al. Blood. 2004;103:3684-3688.
40. OTHER AGGRESSIVE LYMPHOMAS
Mantle Cell Lymphoma
Mantle cell lymphoma: an entity comes of age.
Weisenburger DD, Armitage JO. Blood. 1996;87:4483-4494.
Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma.
Yatabe Y, Suzuki R, Tobinai K, et al. Blood. 2000;95:2253-2261.
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
Rosenwald A, Wright G, Wiestner A, et al. Cancer Cell. 2003;3:185-197.
T-Cell Lymphomas
Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification
Lopez-Guillermo A, Cid J, Salar A, et al. Ann Oncol. 1998;9:849-855.
Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.
Rudiger T, Weisenburger DD, Anderson JR, et al: Non- Hodgkin's Lymphoma Classification Project. Ann Oncol. 2002;13:140-149.
CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features
Stein H, Foss HD, Durkop H, et al. Blood. 2000;96:3681.
Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma.
Gascoyne RD , Aoun P, Wu D, et al. Blood. 1999;93:3913-3921.
Other Aggressive Lymphomas
Primary mediastinal B cell lymphoma: a review of pathology and management.
Van Besien K, Kelta M, Bahaguna P. J Clin Oncol. 2001;19:1855-1864.
Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.
Rodriguez J, McLaughlin P, Hagemeister FB, et al. Blood. 1999;93:2202-2207.
Lymphoblastic lymphoma.
Thomas DA, Kantarjian HM. Hematology Oncol Clin North Am. 2001;15:51-95.
Treatment
Adults and children with small non-cleaved cell lymphoma have similar excellent outcomes when treated with the same chemotherapy regimen.
Magrath I, Adde M, Shad A, et al. J Clin Oncol. 1996;14:925-934.
Chemotherapy for Human Immunodeficiency virus associated Non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy.
Lee R, Lee J, Tang S, et al. J Clin Oncol. 2001;19:2171-2178.
41. POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS
Pathophysiology
Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients.
Opelz G, Henderson R. Lancet. 1993;342:1514-1516.
Posttransplant lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin.
Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Am J Clin Path. 1995;103:748-755.
Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients.
Liebowitz D. N Engl J Med. 1998;338:1413-1421.
Clinical diagnosis/prognosis
Pretransplantation assessment of the risk of lymphoproliferative disorder.
Walker RC, Marshall WG, Strickler JG, et al. Clin Infect Dis. 1995;20:1346-1353.
Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders.
Leblond V, Dhedin N, Mamzer Bruneel MF, et al. J Clin Oncol. 2001;19:772-778.
Treatment
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression.
Nalesnik MA, Jaffe R, Starzl TE, et al. Am J Pathol. 1988;133:173-192.
Aggressive treatment for postcardiac transplant lymphoproliferation.
Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Blood. 1995;86:3333-3340.
Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
Milpied N, Vasseur B, Parquet N, et al. Ann Oncol. 2000;11:113-116.
Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A, Levitsky V, Zou JZ, et al. Blood. 2000;95:807-814.
Review
Epstein-Barr virus-induced posttransplant lymphoproliferative disorders: a ASTS/ASTP EBV-PTLD Task Force and the Mayo Clinic Organized International Consensus Development Meeting.
Paya CV, Fung JJ, Nalesnik MA, et al. Transplantation. 1999;68:1517-1525.
Post-transplant lymphoproliferative disorder: a review.
Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Bone Marrow Transplant. 2003;31:145-155.
42. THE T-CELL SKIN LYMPHOMAS
(mycoses fungoides, Sezary syndrome, and cutaneous T-cell lymphoma)
Diagnosis
Report of the committee on staging and classification of cutaneous T-cell lymphomas.
Bunn PA, Lamberg SI. Cancer Treat Rep. 1979;63:275-278.
Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups.
Sausville EA, Eddy JL, Makuch RW, et al. Ann Intern Med. 1988;109:372-382.
EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.
Willemze R, Kerl H, Sterry W, et al. Blood. 1997;90:354-731.
Treatment
A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides.
Kaye FJ, Bunn PA Jr, Steinber SM, et al. N Engl J Med. 1989;321:1784-1790.
Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome).
Bunn PA Jr, Hoffman SJ, Norris D, et al. Ann Intern Med. 1994;121:592-602.
Interferon in the treatment of cutaneous T-cell lymphoma.
Olsen EA, Bunn PA Jr. Hematol Oncol Clin North Am. 1995;9:1089-1107.
Topical corticosteroids for mycosis fungoides. Experience in 79 patients.
Zackheim HS, Kashani-Sabet M, Amin S. Arch Dermatol. 1998;134:949-954.
Phototherapy for cutaneous T-cell lymphoma.
Baron ED, Stevens SR. Dermatol Ther. 2003;16:303-310.
Prognosis
Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality.
Weinstock MA, Gardstein B. Am J Public Health. 1999;89:1240-1244.
Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution.
Bisaccia E, Gozalez J, Palangio M, et al. J Am Acad Dermatol. 2000;43:263-271.
Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group.
Jones GW, Kacinski BM, Wilson LD, et al. J Am Acad Dermatol. 2002;47:364-370.
Review
Lymphoma of the skin.
Connors JM, His ED, Foss FM. Hematology (Am Soc Hematol Educ Program). 2002:263-82.
43. MATURE T-CELL LEUKEMIA/LYMPHOMAS
Peripheral T-cell lymphomas not otherwise specified
Peripheral T-cell lymphomas: initial features, natural history and prognostic factors in a seris of 174 patients diagnosed according to the R.E.A.L. classification.
Lopez-Guillermo A, Cid J, Salar A, et al. Ann Oncol. 1998;9:849-855.
Predictive capacity of of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.
Ansell SM, Habermann TM, Kurtin PJ, et al. J Clin Oncol. 1997;15:2296-2301.
Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas: Groupe d'Etudes des Lymphomes de l'Adulte ( GELA).
Gisselbrecht C, Gaulard P, Lepage E, et al. Blood. 1998;92:76-82.
Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.
Rudiger T, Weisenburger DD, Anderson JR, et al. Ann Oncol. 2002;13:140-149.
Anaplastic large-cell lymphoma
Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project.
Weisenburger DD, Anderson JR, Diebold J, et al. Am J Hematol. 2001;67:172-178.
Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
Drexler HG, Gignac SM, von Wasielewski R, et al. Leukemia. 2000;14:1533-1559.
AILD
Angioimmunoblastic lymphadenopathy with dysproteinemia: emphasis on pathogenesis and treatment.
Sallah S, Gagnon GA. Acta Haematol. 1998;99:57-64.
Hepatosplenic gamma delta T-cell lymphoma
Hepatosplenic gamma delta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.
Belhadj K, Reyes F, Farcet JP, et al. Blood. 2003;102:4261-4269.
ATLL
Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma.
Shimoyama M, and members of the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428-437.
Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo.
Mortreux F, Gabet AS, Wattel E. Leukemia. 2003;17:26-38.
Management of adult T-cell Leukaemia/Lymphoma.
Pawson R, Mufti GJ, Pagliuca A. Br J Haematol. 1998;100:453-458.
Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine.
Gill PS, Harrington W, Kaplan MH, et al. N Engl J Med. 1995;332:1744-1748.
44. LYMPHOPLASMACYTIC LYMPHOMA, WALDENSTROM’S MACROGLOBULINEMIA, AND CASTLEMAN’S DISEASE
Lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia
DIAGNOSIS AND PROGNOSIS
Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility.
Gobbi PG, Bettini R, Montecucco C, et al. Blood. 1994;83:2939-2945.
Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32).
Iida S, Rao PH, Ueda R, Chaganti RS, Dalla-Favera, R. Leuk Lymphoma. 1999;34:25-33.
TREATMENT
Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy.
Mazzaro C, Franzin F, Tulissi P, et al. Cancer. 1996;77:2604-2613.
Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
Dhodapkar MV, Jacobson JL, Gertz MA, et al. Blood. 2001;98:41-48.
REVIEW
Waldenstrom's macroglobulinemia.
Dimopoulos MA, Alexanian R. Blood. 1994;83:1452-1459.
Waldenstrom’s macroglobulinemia: clinical features, complications, and management.
Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. J Clin Oncol. 2000;18:214-226.
B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders.
Pangalis GA, Angelopoulou MK, Vassilakopoulos TP, Siakantaris, MP, Kittas C. Semin Hematol. 1999;36:104-114.
Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders.
Tallman MS, Hakimian D. Blood. 1995;86:2463-2474.
Images in clinical medicine: Waldenstrom's macroglobulinemia.
Wulf G, Pool S. N Engl J Med. 2001;344:816.
Castleman’s disease
PATHOGENESIS
Localized mediastinal lymph node hyperplasia resembling thymoma.
Castleman B, Iverson L, Menendez VP. Cancer. 1956;9:822-830.
Herpes-like DNA sequences, AIDS-related tumors, and Castleman's disease.
Dupin N, Gorin I, Deleuze J, Agut H, Huraux JM, Escande JP. N Engl J Med. 1995;333:798.
Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease.
Belec L, Mohamed AS, Authier FJ, et al. Blood. 1999;93:3643-3653.
TREATMENT
Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy.
Corbellino M, Bestetti G, Scalamogna C, et al. Blood. 2001;98:3473-3475.
REVIEW
The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature.
Bowne WB, Lewis JJ, Filippa DA, et al. Cancer. 1999;85:706-717.
Images in clinical medicine: Castleman's disease.
Sickel JZ. N Engl J Med. 1995;333:776.
45. CHRONIC LYMPHOCYTIC LEUKEMIA
Pathophysiology/Epidemiology
Clinical staging of chronic lymphocytic leukemia.
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Blood. 1975;46:219-234.
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.
Binet JL, Auquier A, Dighiero G, et al. Cancer. 1981;48:198-206.
The American College of Surgeons Commission on Cancer and the American Cancer Society: the National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia.
Diehl LF, Karnell LH, Menck HR. Cancer. 1999;86:2684-2692.
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Damle RN, Wasil T, Fais F, et al. Blood. 1999;94:1840-1847.
Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia.
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Blood. 1999;94:1848-1854.
Genomic aberrations and survival in chronic lymphocytic leukemia.
Dohner H, Stilgenbauer S, Benner A, et al. N Engl J Med. 2000;343:1910-1916.
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
Rassenti LZ, Huynh L, Toy TL, et al. N Engl J Med. 2004;351:893.
Treatment
National Cancer Institute–sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
Cheson BD, Bennett JM, Grever M, et al. Blood. 1996;87:4990-4991.
Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia.
Johnson S, Smith AG, Loffler H, et al: The French Cooperative Group on CLL. Lancet. 1996;347:1432-1438.
Chlorambucil in indolent chronic lymphocytic leukemia: French Cooperative Group on Chronic Lymphocytic Leukemia.
Dighiero G, Maloum K, Desablens B, et al. N Engl J Med. 1998;338:1506-1514.
Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: a randomized, controlled clinical trial.
Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia.
N Engl J Med. 1988;319:902-907.
Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials.
CLL Trialists’ Collaborative Group. J Natl Cancer Inst. 1999;91:861-868.
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.
Mauro FR, Foa R, Cerretti R, et al. Blood. 2000;95:2786-2792.
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR, Peterson BL, Appelbaum FR, et al. N Engl J Med. 2000;343:1432-1438.
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.
Huhn D, von Schilling C, Wilhelm M, et al: German Chronic Lymphocytic Leukemia Study Group. Blood. 2001;98:1326-1331.
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Leporrier M, Chevret S, Cazin B, et al: French Cooperative Group on Chronic Lymphocytic Leukemia. Blood. 2001;98:2319-2325.
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Keating MJ, Flinn I, Jain V, et al. Blood. 2002;99:3554-3561.
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
Weiss MA, Maslak PG, Jurcic JG, et al. J Clin Oncol. 2003;21:1278-1284.
Review
Allogeneic and autologous transplantation for chronic lymphocytic leukemia.
van Besien K, Keralavarma B, Devine S, Stock W. Leukemia. 2001;15:1317-1325.
46. HAIRY CELL LEUKEMIA
Diagnosis
Hairy cell leukemia: a clinical review based on 71 cases.
Golomb HM, Catovsky D, Golde DW. Ann Intern Med. 1978;89:677-683.
The diagnosis and differential diagnosis of hairy cell leukemia in bone marrow and spleen.
Burke JS, Rappaport H. Semin Oncol. 1984;11:334-346.
The immunophenotype of hairy cell leukemia (HCL): proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes.
Matutes E, Morilla R, Owusu-Ankomah K, Houliham A, Meeus P, Catovsky D. Leuk Lymphoma. 1994;14:57-62.
Treatment
PENTOSTATIN
Pentostatin in the treatment of advanced hairy cell leukemia.
Kraut EH, Bouroncle BA, Grever MR. J Clin Oncol. 1989;7:168-172.
Long-term results with 2'-deoxycoformycin in hairy cell leukemia.
Catovsky D, Matutes E, Talavera JG, et al. Leuk Lymphoma. 1994;14:109-113.
Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia.
Urba WJ, Baseler MW, Kopp WC, et al. Blood. 1989;73;38-46.
Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin.
Kraut EH, Grever MR, Bouroncle BA. Blood. 1994;84:4061-4063.
CLADRIBINE
Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.
Piro LD, Carrera CJ, Carson DA, Beutler E. N Engl J Med. 1990;322:1117-1121.
Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia: a new treatment schedule effective and safer in preventing infectious complications.
Lauria F, Bocchia M, Marotta G, Raspadori D, Zinzani PL, Rondelli D. Blood. 1997;89:1838-1839.
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
Goodman GR, Burian C, Koziol JA, Saven A. J Clin Oncol. 2003;21:891-896.
MONOCLONAL THERAPIES
Rituximab in relapsed or refractory hairy cell leukemia.
Thomas DA, O'Brien S, Bueso-Ramos C, et al. Blood. 2003;102:3906-3911.
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
Kreitman RJ, Wilson WH, Bergeron K, et al. N Engl J Med. 2001;345:241-247.
Review
Newer Purine Analogues for the Treatment of Hairy-Cell Leukemia.
Saven A, Piro L. N Engl J Med. 1994;330:691.
47. TUMOR LYSIS SYNDROME
Diagnosis and Pathophysiology
Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma.
Hande KR, Garrow GC. Am J Med. 1993;94:133-139.
Tumor lysis syndrome in small cell carcinoma and other solid tumors.
Kalemkerian GP, Darwish B, Varterasian ML. Am J Med. 1997;103:363-367.
Incidence and treatment of tumor lysis syndrome in patients with acute leukemia.
Razis E, Arlin ZA, Ahmed T, et al. Acta Haematol. 1994;91:171-174.
Tumour lysis syndrome: new therapeutic strategies and classification.
Cairo MS, Bishop M. Br J Haematol. 2004;127:3-11.
Incidence and pathogenesis of tumor lysis syndrome.
Locatelli F, Rossi F. Contrib Nephrol. 2005;147:61-68.
Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma.
Stapleton FB, Strother DR, Roy S 3rd, Wyatt RJ, McKay CP, Murphy SB. Pediatrics. 1988;82:863-869.
Treatment
Allopurinol: intravenous use for prevention and treatment of hyperuricemia.
Smalley RV, Guaspari A, Haase-Statz S, Anderson SA, Cederberg D, Hohneker JA. J Clin Oncol. 2000;18:1758-1763.
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
Coiffier B, Mounier N, Bologna S, et al: Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma. J Clin Oncol. 2003;21:4402-4406.
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome: a Meeting Report, Dallas, Texas, January 2002.
Navolanic PM, Pui CH, Larson RA, et al. Leukemia. 2003;17:499-514.
Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
Ribeiro RC, Pui CH. Clin Lymphoma. 2003;3:225-232.
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Goldman SC, Holcenberg JS, Finklestein JZ, et al. Blood. 2001;97:2998-3003.
Review
Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome.
Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Am J Med. 2004;116:546-554.
Tumor lysis syndrome.
Jeha S. Semin Hematol. 2001;38:4-8.
Hyperuricemic syndromes in cancer patients.
Tsimberidou AM, Keating MJ. Contrib Nephrol. 2005;147:47-60.
48. DISSEMINATED INTRAVASCULAR COAGULATION
Pathophysiology
Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice.
Levi M, Dorffler-Melly J, Reitsma P, Buller H, Florquin S, van der Poll T, Carmeliet P. Blood. 2003;101:4823-4827.
Advances in the understanding of pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies.
Levi M, de Jonge E, van der Poll T, ten Cate H. Semin Thromb Hemost. 2001;27:569-575.
Diagnosis
Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases.
Siegal T, Seligsohn U, Aghai E, Modan M. Thromb Haemost. 1978;39:122.
Screening tests of disseminated intravascular coagulation: guidelines for rapid and specific laboratory diagnosis.
Yu M, Nardella A, Pechet L. Crit Care Med. 2000;28:1777-1780.
Diagnosis of disseminated intravascular coagulation: role of D-dimer.
Carr JM, McKinney M, McDonagh J. Am J Clin Pathol. 1989;91:280-287.
Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compare patterns of antithrombin III, protein C, and protein S deficiencies.
Fourrier F, Chopin C, Goudemand J, et al. Chest .1992;101:816-823.
Treatment
Treatment of disseminated intravascular coagulation.
Feinstein, DI. Semin Thromb Haem. 1998;14:351-362.
Disseminated intravascular coagulation and sustained systemic inflammatory response syndrome predict organ dysfunctions after trauma: application of clinical decision analysis.
Gando S, Nanzaki S, Kemmotsu O. Ann Surg. 1999;229:121-127.
Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR, Vincent JL, Laterre PF, et al. N Engl J Med. 2001;344:699-709.
Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.
Warren BL, Eid A, Singer P, et al. JAMA. 2001;286:1869-1878.
Review
Disseminated intravascular coagulation.
Levi M, Cate HT. N Engl J Med. 1999;341:586-592.
Disseminated intravascular coagulation: old disease, new hope.
Toh CH, Dennis M. BMJ. 2003;327:4823-4827.
49. SUPERIOR VENA CAVA SYNDROME
Treatment
Multimodality treatment of malignant superior vena caval syndrome.
Roberts JR, Bueno R, Sugarbaker DJ. Chest. 1999;116:835-837.
Stent placement in superior vena cava syndrome.
Courtheoux P, Alkofer B, Al Refai M, Gervais R, Le Rochais JP, Icard P. Ann Thorac Surg. 2003;75:158-161.
Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies.
Boraks P, Seale J, Price J, et al. Br J Haematol. 1998;101:483-486.
Safety and efficacy of thrombolytic therapy for superior vena cava syndrome.
Gray, BH, Olin, JW, Graor, RA, Young JR, Bartholomew JR, Ruschhaupt WF. Chest. 1991;99:54-59.
Superior vena cava obstruction: bypass using spiral vein graft.
Doty, DB.
Ann Thorac Surg. 1999;67:1111-1116.
Open surgical and endovascular treatment of superior vena cava syndrome caused by nonmalignant disease.
Kalra, M, Gloviczki, P, Andrews, JC, et al. J Vasc Surg. 2003;38:215-223.
Review
The superior vena cava syndrome.
Schechter, MM. Am J Med Sci. 1954;227:46.
Diagnosis and management of superior vena cava syndrome.
Markman, M. Cleve Clin J Med. 1999;66:59-61.
50. PARANEOPLASTIC SYNDROMES
Pathophysiology
Neurologic disorders in patients with small cell lung cancer.
Sculier J-P, Feld R, Evans WK, et al. Cancer 1987;60:2275-2283.
Malignant thymoma associated with autoimmune diseases: a retrospective study and review of the literature.
Levy Y, Afek A, Sherer Y, et al. Semin Arthritis Rheum. 1998;28:73-79.
Motor neuron disease and malignancy.
Younger DS. Muscle Nerve. 2000;23:658-660.
Paraneoplastic syndromes involving the nervous system.
Darnell, RB, Posner, JB. N Engl J Med. 2003;349:1543-1554.
Diagnosis
The role of [(18)F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders.
Rees, JH, Hain, SF, Johnson, MR, Hughes, RA. Brain. 2001;124:2223-2231.
Treatment
Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.
Keime-Guibert, F, Graus, F, Fleury, A, et al. J Neurol Neurosurg Psychiatry. 2000;68:479-482.
Review
Paraneoplastic neurologic syndromes: pathogenesis and physiopathology.
Dalmau, J, Gultekin, HS, Posner, JB. Brain Pathol. 1999;9:275-284.
Paraproteinemic neuropathies.
Vital A. Brain Pathol. 2001;11:399-407.
51. Hematologic Aspects of Pregnancy
Epidemiology and Pathogenesis: Hypercoaguable States in Pregnancy, Fetal Loss, Venous Thromboembolism, and Thrombocytopenia
Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study.
Lynch A, Marlar R, Murphy J, et al. Ann Intern Med. 1994;120:470-475.
Pregnancy loss in the antiphospholipid antibody syndrome – a possible thrombogenic mechanism.
Rand JH, Wu XX, Andree HA, et al. N Engl J Med. 1997;337:154-160.
Increased fetal loss in women with heritable thrombophilia.
Preston FE, Rosendaal FR, Walker ID, et al. Lancet. 1996;348:913-916.
Increased frequency of genetic thrombophilia in women with complications of pregnancy.
Kupferminc MJ, Eldor A, Steinman N, et al. N Engl J Med. 1999;340:9-13.
Thrombophilic disorders and fetal loss: a meta-analysis.
Rey, E, Kahn, SR, David, M, Shrier, I. Lancet. 2003;361:901-908.
Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.
Gerhardt A, Scharf RE, Beckmann MW, et al. N Engl J Med. 2000;342:374-379.
Frequency of pregnancy related venous thromboembolism in anticoagulant factor deficient women: Implications for prophylaxis.
Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism.
Pabinger I, Grafenhofer H, Kyrle P, et al. Blood. 2002;100:1060-1062.
Fetal thrombocytopenia and its relationship to maternal thrombocytopenia.
Burrows RF, Kelton JG. N Engl J Med. 1993;329:1463-1466.
Incidentally detected thrombocytopenia in healthy mothers and their infants.
Burrows RF, Kelton JG. N Engl J Med. 1988;319:142-145.
Treatment
Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).
Rai R, Cohen H, Dave M, and Regan L. BMJ. 1997;314:253-257.
Safety of withholding heparin in pregnant women with a history of venous thromboembolism: Recurrence of Clot in This Pregnancy Study Group.
Brill-Edwards P, Ginsberg JS, Gent M, et al. N Engl J Med. 2000;343:1439-1444.
Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Thromb Haemost. 2000;83:693-697.
Low molecular weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder.
Gris JC, Mercier E, Quere I, et al. Blood. 2004;103:3695-3699.
Anticoagulation of pregnant women with mechanical heart valves.
Ginsberg JS, Chan WS, Bates SM, Kaatz S. Arch Intern Med. 2003;163:694-698.
Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study.
Koshy M, Burd L, Wallace D, Moawad A, Baron J. N Engl J Med. 1988;319:1447-1452.
Review
Management of venous thromboembolism during pregnancy.
Ginsberg JS, Bates SM. J Thromb Haemost. 2003;1:1435-1442.
Use of antithrombotic agents during pregnancy.
Ginsberg JS, Greer I, Hirsh J. Chest. 2001;119:122S-131S.
Clinical management of thrombophilia related placental vascular complications.
Brenner B. Blood. 2004;103:4003-4009.
52. BONE MARROW TRANSPLANTATION
Historical
Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy.
Thomas ED, Lochte HL Jr, Lu WC, Ferrebee J.W. N Engl J Med. 1957;257:491-496.
Supralethal whole body irradiation and isologous marrow transplantation in man.
Thomas ED, Lochte HL Jr, Cannon JH, Sahler OD, Ferrebee JW. J Clin Invest. 1959;38:1709-1716.
GVHD and GVL
Antileukemic effect of graft-versus host disease in human recipients of allogeneic-marrow grafts.
Weiden PL, Flournoy N, Thomas ED, et al. N Engl J Med. 1979;300:1068-1073.
Antileukemic effect of chronic graft versus-host disease: contribution to improved survival after allogeneic marrow transplantation.
Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. N Engl J Med. 1981;304:1529-1533.
Graft-versus-leukemia reactions after bone marrow transplantation.
Horowitz MM, Gale RP, Sondel PM, et al. Blood. 1990;75:555-562.
Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. N Engl J Med. 1994;330:100-106.
Prevention of graft versus host disease by inactivation of host antigen-presenting cells.
Shlomchik WD, Couzens MS, Tang CB, et al.Science. 1999;285:412-415.
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.
Miklos DB, Kim HT, Miller KH, et al. Blood. 2005;105:2973-2978.
Solid Tumors and BMT
Solid cancers after bone marrow transplantation.
Curtis RE, Rowlings PA, Deeg HJ, et al. N Engl J Med. 1997;336:897-904.
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
Stadtmauer EA, O’Neill A, Goldstein LJ, et al. N Engl J Med. 2000;342:1069-1076.
Nonmyeloablative Transplantation
Transplant-lite: induction of graft-versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Khouri IF, Keating M, Korbling M, et al. J Clin Oncol. 19989;16:2817-2824.
Umbilical Cord Blood Transplantation
Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients.
Kurtzberg J, Laughlin M, Graham ML, et al. N Engl J Med. 1996;335:157-166.
Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.
Rocha V, Labopin M, Sanz G, et al. N Engl J Med. 2004;351:2276-2285.
Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.
Laughlin MJ, Eapen M, Rubinstein P, et al. N Engl J Med. 2004;351:2265-2275.
Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies.
Takahashi S, Iseki T, Ooi J, et al. Blood. 2004;104:3813-3820.
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy.
Barker JN, Weisdorf DJ, DeFor TE, et al. Blood. 2005;105:1343-1347.
Review
Cytokine dysregulation and acute graft versus-host disease.
Antin JH, Ferrara JL. Blood. 1992;80:2964-2968.
Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect.
Champlin R, Khouri I, Komblau S, Molidrem J, Giralt S. Oncology (Huntingt). 1999;13:621-628.
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
Ho VT, Soiffer RJ. Blood. 2001;98:3192-3204.
Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?
Korbling M, Anderlini P. Blood. 2001;98:2900-2908.
How I treat chronic graft-versus-host disease.
Vogelsang GB. Blood. 2001;97:1196-1201.
53. HEMATOLOGIC ASPECTS OF HIV
Diagnosis and Pathophysiology
Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden: AIDS/Cancer study group.
Cote TR, Biggar RJ, Rosenberg PS, et al. Int J Cancer. 1997;73:645-650.
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Little RF, Pittaluga S, Grant N, et al. Blood. 2003;101:4653-4659.
Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.
Nador RG, Cesarman E, Chadburn A, et al. Blood. 1996;88:645-656.
Epstein-Barr virus in AIDS-related primary central nervous system lymphoma.
MacMahon EM, Glass JD, Hayward SD, et al. Lancet. 1991;338:969-973.
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial.
Richman DD, Fischl MA, Grieco MH, et al. N Engl J Med. 1987;317:192-197.
Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project.
Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Blood. 1998;91:301-308.
Pathogenesis and pathophysiology of anemia in HIV infection.
Kreuzer KA, Rockstroh JK. Ann Hematol. 1997;75:179-87.
Cytopenias in HIV infection: mechanisms and alleviation of hematopoietic inhibition.
Koka PS, Reddy ST. Curr HIV Res. 2004;2:275-282.
Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection.
Ballem PJ, Belzberg A, Devine DV, et al. N Engl J Med. 1992;327:1779-1784.
GPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia.
Nardi MA, Liu L-X, Karpatkin S. Proc Natl Acad Sci U S A. 1997;94:7589-7594.
Role of molecular mimickry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia.
Li Z, Nardi MA, Karpatkin S. Blood. 2005;106:572-576.
T cell dynamics in HIV-1 infection.
Douek DC, Picker LJ, Koup RA. Annu Rev Immunol. 2003;21:265-304.
Treatment
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Little RF, Pittaluga S, Grant N, et al. Blood. 2003;101:4653-4659.
AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. J Clin Oncol. 2005;23:4430-4438.
Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating factors, erythropoietin, and interleukin-2.
Armstrong WS, Kazanjian P. Clin Infect Dis. 2001;32:766-773.
Anemia in HIV infection: clinical impact and evidence-based management strategies.
Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M: Anemia in HIV Working Group. Clin Infect Dis. 2004;38:1454-1463.
Review
Human immunodeficiency virus hematology.
Volberding PA, Baker KR, Levine AM. Hematology (Am Soc Hematol Educ Program). 2003;294-313.
Haematological aspects of HIV infection.
Evans RH, Scadden DT. Baillieres Best Pract Res Clin Haematol. 2000;13:215-230.
Biology of anemia, differential diagnosis, and treatment options in human immunodeficiency virus infection.
Claster S. J Infect Dis. 2002;185:S105-S109.
HIV-related thrombocytopenia.
Scaradavou A. Blood Rev. 2002;16:73-76.
Human immunodeficiency virus infection and thrombotic microangiopathy.
Hymes KB, Karpatkin S. Semin Hematol. 1997;34:117-125.
54. PLASMAPHERESIS AND IVIG
Plasmapheresis
TREATMENT
Use of cellular and plasma apheresis in the critically ill patient, II: clinical indications and applications.
Linenberger ML, Price TH. J Intensive Care Med. 2005;20:88-103.
Applications of therapeutic apheresis in patients with malignant disease.
Pineda AA, Vamvakas EC. Oncologist. 1997;2:94-103.
Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis.
Smith JW, Weinstein R, for the AHCKL. Transfusion. 2003;43:820-822.
Plasmapheresis in immune hematology: review of clinical outcome data with respect to evidence-based medicine and clinical experience.
von Baeyer H. Ther Apher Dial. 2003;7:127-140.
IVIG
TREATMENT
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
George JN, Woolf SH, Raskob GE, et al. Blood. 1996;88:3-40.
Intravenous immunoglobulin treatment in hematological diseases.
Otten A, Bossuyt PM, Vermeulen M, Brand A. Eur J Haematol. 1998;60:73-85.
Applications of intravenous immunoglobulin in haematology.
Todd AA, Yap PL. Blood Rev. 1992;6:105-117.
Self-reported initial management of childhood idiopathic thrombocytopenic purpura: results of a survey of members of the American Society of Pediatric Hematology/Oncology, 2001.
Vesely SK, Buchanan GR, Adix L, et al. J Pediatr Hematol Oncol. 2003;25:130-133.
Current management of adult idiopathic thrombocytopenic purpura in practice: a cohort study of 201 patients from a single center.
Zimmer J, Andres E, Noel E, Koumarianou A, Blickle JF, Maloisel F. Clin Lab Haematol. 2004;26:137-142.
Review
Blood component collection by apheresis.
Burgstaler EA. J Clin Apheresis. Prepublished May 6, 2005.
Use of cellular and plasma apheresis in the critically ill patient, I: technical and physiological considerations.
Linenberger ML, Price TH. J Intensive Care Med. 2005;20:18-27.
Plasmapheresis: technique and complications.
Reimann PM, Mason PD. Intensive Care Med. 1990;16:3-10.
55. TRANSFUSION MEDICINE
Alloantigen systems
Erythrocyte blood group antigens: polymorphisms of functionally important molecules.
Telen MJ. Semin Hematol 1996;33:302-314.
Terminology for blood group antigens and genes – historical origins and guidelines in the new millennium.
Garratty G, Dzik W, Issitt PD, Lublin DM, Reid ME, Zelinski T. Transfusion. 2000;40:477-489.
Platelet and neutrophil alloantigen genotyping in clinical practice.
McFarland JG. Transf Clin Biol. 1998;5:13-21.
Blood donation, collection, and component preparation
Standards for Blood Banks and Transfusion Services, 21st ed.
American Association of Blood Banks. Bethesda, MD: American Association of Blood Banks, 2002.
Improving the efficacy of preoperative autologous blood donation in patients with low hematocrit: a randomized, double-blind, controlled trial of recombinant human erythropoietin.
Price TH, Goodnough LT, Vogler WR, et al. Transfusion. 1996;36:29-36.
Blood component modifications
Universal WBC reduction: the case for and against.
Vamvakas EC, Blajchman MA. Transfusion. 2001;41:691-712.
The irradiation of blood and blood components to reduce graft-versus-host disease: technical issues and guidelines.
Moroff G, Luban NL. Transfuse Med Rev. 1997;11:15-26.
Red blood cell transfusion
Perioperative red blood cell transfusion.
Consensus conference. JAMA. 1998;260:2700-2703.
Practice strategies for elective red blood cell transfusion.
American College of Physicians. Ann Intern Med. 1992;116:403-406.
Platelet transfusion
Final statement from the consensus conference on platelet transfusion.
Contreras M. Transfusion. 1998;38:796-797.
Current issues with platelet transfusion in patients with cancer.
McCullough J. Semin Hematol. 2000;37:3-10.
Granulocyte transfusion
Granulocyte transfusion therapy: update on potential clinical applications.
Hubel K, Dale DC, Liles WC. Curr Opin Hematol. 2001;8:161-164.
Complications of transfusions
The role of the plasma from platelet concentrates in transfusion reactions.
Heddle NM, Klama L, Singer J, et al. N Engl J Med. 1994;331:670-671.
Pathogenesis and management of hemolytic transfusion reactions.
Greenwalt TJ. Semin Hematol. 1981;18:84-94.
Transfusion-associated graft-versus-host disease.
Schroeder ML. Br J Haematol. 2002;117:275-287.
Current status of microbial contamination of blood components: summary of a conference.
Klein HG, Dodd RY, Ness PM, Fratantoni JA, Nemo GJ. Transfusion. 1997;37:95-101.
Current viral risks of blood and blood products.
Dodd RY. Ann Med. 2000;32:469-474.
Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors.
Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Blood. 2003;101:454-462.
Therapeutic apheresis
An approach to evidence-based therapeutic apheresis
B.C. McLeod. J. Clin Apheresis 17: 124-132 (2002)
Complications of plasma exchange
D.M. Sutton, R.C. Nair, G. Rock. Transfusion 29: 124-127 (1989)
Review
Transfusion medicine. Blood transfusion.
L.T. Goodnough, M.E. Brecher, M.H. Kanter, J.P. AuBuchon N Engl J Med 340: 438-447 (1999)
Oncology Reading List
Updated November 2007
Adrenocortical Carcinoma
Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2004;60(3):273-87.
Chen DY, Sosa RE, Scherr DS. Treatment of adrenocortical carcinoma: contemporary outcomes. Curr Urol Rep 2004;5(1):65-72.
Terzolo M, Angeli A, Fassnacht M, Daffara F, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007 Jun 7;356(23):2372-80. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17554118
Alternative Therapy
Gertz MA, Bauer BA. Caring (really) for patients who use alternative therapies for cancer. J Clin Oncol 2001 Dec 1;19(23):4346-9.
Weiger WA, Smith M, Boon H et al. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Internal Med 2002;137:889-903.
DiGianni LM, Garber JE, Winer EP. Complementary and alternative medicine use among women with breast cancer. JCO 2002;20: 34s-38s.
Wilkinson S, Chodak GW. Critical review of complementary therapies for prostate cancer. JCO 2003;21(11): 2199-2210.
Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004;22(12):2489-503.
Ladas EJ, Jacobson JS, Kennedy DD, et al. Antioxidants and cancer therapy: a systematic review. J Clin Oncol 2004;22(3):517-28.
Amyloidosis
Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002 Jun 15;99(12):4276-82.
Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349:583-596.
Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006 Oct 15;108(8):2520-30. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16794250
Jaccard A, Moreau P, Leblond V, Leleu X, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007 Sep 13;357(11):1083-93.
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17855669
Anal Cancer
DP Ryan and Mayer RJ. Carcinoma of the anal canal. NEJM 2000; 342:792-800.
Benign Lymphoproliferative Diseases
Benign lymphoproliferative disorders [includes Castleman's disease, angioimmunoblastic lymphadenopathy with dysproteinemia]. Semin Oncol 20(6), 1993 (entire issue).
Bladder Cancer
Dimopoulos MA and Moulopoulos LA. Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder. JCO 1998;16:1601-1612.
Gospodarowicz M. Radiotherapy and organ preservation in bladder cancer: are we ignoring the evidence? J Clin Oncol 2002 Jul 15;20(14):3048-50.
Bone Marrow and Stem Cell Transplantation
Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001 Nov 15;98(10):2900-8. http://www.bloodjournal.org/cgi/content/full/98/10/2900
Ho VT and Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3192-3204.,http://www.bloodjournal.org/cgi/content/full/98/12/3192
Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001 Mar 1;97(5):1196-201. http://www.bloodjournal.org/cgi/content/full/97/5/1196
Socié G, Salooja N, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003; 101: 3373-3385
Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004;103(3):767-76.
Brain Metastases
Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22(17):3608-17.
Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005 Sep 1;23(25):6207-19. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16135488
Chamberlain MC. Neoplastic meningitis. J Clin Oncol. 2005 May 20;23(15):3605-13. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15908671
Brain Tumors
DeAngelis LM. Brain tumors. N Engl J Med 2001 Jan 11;344(2):114-23.
Sønderkær S, Schmiegelow M, et al. Long-term neurological outcome of childhood brain tumors treated by surgery only. JCO 2003;21(7): 1347-1351.
Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005 Nov 10;353(19):2012-24. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16282176
Stupp R, Mason WP, van den Bent MJ, Weller M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15758009
Breast Cancer
Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. NEJM 1996; 335:1785-1791.
Eisen A, Rebbeck TR, et al. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. JCO 2000; 18:1980.
Vogel VG. Reducing the risk of breast cancer with tamoxifen in women at increased risk. J Clin Oncol 2001 Sep 15;19(18 Suppl):87S-92S.
Col NF, Hirota LK, Orr RK, Erban JK, et al. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001 Apr 15;19(8):2357-63.
DiGianni LM, Garber JE, Winer EP. Complementary and alternative medicine use among women with breast cancer. JCO 2002;20: 34s-38s.
Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. NEJM 2002; 346:2025-2032.
Fletcher SW, Elmore JG. Mammographic screening for breast cancer. N Engl J Med 2003;348(17):1672-80.
Domchek SM, Eisen A, et al. Application of breast cancer risk prediction models in clinical practice. JCO 2003;21(4): 593-601.
Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003;348(23):2339-47.
Seidman AD. Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism? J Clin Oncol 2003;21(4):577-9.
Bouchardy C, Rapiti E, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. JCO 2003;21(19): 3580-3587.
Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431-2442.
Kaufmann M, von Minckwitz G, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. JCO 2003;21(13): 2600-2608.
Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21(17):3357-65.
Overmoyer B. Combination chemotherapy for metastatic breast cancer: reaching for the cure. J Clin Oncol 2003;21(4):580-2.
Burstein HJ, Polyak K, et al. Ductal carcinoma in situ of the breast. N Engl J Med 2004;350(14):1430-41.
Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29;353(26):2747-57.
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16382061
Hartmann LC, Sellers TA, Frost MH, Lingle WL, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005 Jul 21;353(3):229-37. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16034008
Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med. 2005 Oct 20;353(16):1734-6.,http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16236745
Geyer CE, Forster J, Lindquist D, Chan S, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733-43. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17192538
Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007 Jul 12;357(2):115-23. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17625123
Cancer Screening
Barry MJ. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001 May 3;344(18):1373-7.
Brandon TH. Behavioral tobacco cessation treatments: yesterday's news or tomorrow's headlines? J Clin Oncol 2001 Sep 15;19(18 Suppl):64S-68S.
Sawaya GF, Brown AD, Washington AE, Garber AM. Clinical practice. Current approaches to cervical-cancer screening. N Engl J Med 2001 May 24;344(21):1603-7.
Kinsinger LS, Harris R, Woolf SH, Sox HC, et al. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002 Jul 2;137(1):59-69.
http://www.annals.org/issues/v137n1/full/200207020-00017.html
Greenwald P. Cancer prevention clinical trials. J Clin Oncol 2002 Sep 15;20(18 Suppl):14S-22S.
Pignone M, Rich M, Teutsch SM, Berg AO, et al. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002 Jul 16;137(2):132-41. http://www.annals.org/issues/v137n2/full/200207160-00015.html
U.S. Preventive Services Task Force. Screening for Prostate Cancer: Recommendation and Rationale. Ann Internal Med 2002; 137: 915-916.,http://www.annals.org/issues/v137n11/full/200212030-00013.html
Fletcher SW, Elmore JG. Mammographic screening for breast cancer. N Engl J Med 2003; 348:1672-1680.
Khoury MJ, McCabe LL and McCabe ERB. Genomic Medicine: Population Screening in the Age of Genomic Medicine. New England Journal of Medicine. 348(1):50-58, January 2, 2003.
Smith RA, Cokkinides V, and Eyre HJ. American Cancer Society Guidelines for the Early Detection of Cancer, 2003. CA Cancer J Clin 2003; 53:27-43. http://caonline.amcancersoc.org/cgi/content/full/53/1/27
DePriest PD, DeSimone CP. Ultrasound screening for the early detection of ovarian cancer. JCO 2003;21: 194s-199s.
Mulshine JL, Sullivan DC. Clinical practice. Lung cancer screening. N Engl J Med. 2005 Jun 30;352(26):2714-20. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15987920
Carcinoid
C.G. Moertel and others. The management of patients with advanced carcinoid tumors and islet cell carcinoma. Am. Intern. Med. 120: 302, 1994.
Kulke MH and Mayer RJ. Carcinoid Tumors. NEJM 1999; 340:858-868.
Cervical Cancer
Cannistra SA and Niloff JM. Cancer of the uterine cervix. NEJM 1996; 334:1030.
Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007 Jul 10;25(20):2952-65. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17617527
Long HJ 3rd. Management of metastatic cervical cancer: review of the literature. J Clin Oncol. 2007 Jul 10;25(20):2966-74.,http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17617528
Chemotherapy and Cancer Treatment Toxicity
Singal PK, Iliskovic N. Current concepts: doxorubicin-induced cardiomyopathy. NEJM 1998; 339:900-905.
Preventing the Toxicity of Chemotherapy. Semin Oncol 25(5), 1998 (entire issue).
Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001 Mar 1;97(5):1514-6. http://www.bloodjournal.org/cgi/content/full/97/5/1514
Kirkwood JM, Bender C, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. JCO 2002;20(17): 3703-3718.
Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004;104(3):655-8.
Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004;22(11):2233-9.
Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22(2):322-9.
Clinical Practice Guidelines
National Comprehensive Cancer Network (NCCN),http://www.nccn.org/physician_gls/index.html
Rizzo JD, Lichtin AE, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100: 2303-2320. http://www.bloodjournal.org/cgi/content/full/100/7/2303?maxtoshow=&HITS=100&hits=100&RESULTFORMAT=1&searchid=1067831154517_8052&stored_search=&FIRSTINDEX=0&flag=HWREVIEW&sortspec=relevance&fdate=1/1/2002&journalcode????!? ???!
Ozols RF, Herbst RS, Colson YL, Gralow J, et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2007 Jan 1;25(1):146-62. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17158528
Colorectal Cancer
Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000 Jun 29;342(26):1960-8.
Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001 Nov 1;19(21):4097-106.
Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348(10):919-32.
Ayanian JZ, Zaslavsky AM, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort JCO 2003;21(7): 1293-1300.
Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22(16):3408-19.
Levine JS, Ahnen DJ. Clinical practice. Adenomatous polyps of the colon. N Engl J Med. 2006 Dec 14;355(24):2551-7. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17167138
Bosset JF, Collette L, Calais G, Mineur L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006 Sep 14;355(11):1114-23. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16971718
Psaty BM, Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med. 2006 Aug 31;355(9):885-95. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16943408
Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007 May 24;356(21):2131-42. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17522398
Endocrine Neoplasms
Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004;83(1):43-83.
Gertner ME, Kebebew E. Multiple endocrine neoplasia type 2. Curr Treat Options Oncol 2004 Aug;5(4):315-25.
Endometrial Cancer
Sonoda Y. Optimal therapy and management of endometrial cancer. Expert Rev Anticancer Ther 2003;3(1):37-47.
Santin AD, Bellone S, O'Brien TJ, et al. Current treatment options for endometrial cancer. Expert Rev Anticancer Ther 2004;4(4):679-89.
Schmeler KM, Lynch HT, Chen LM, Munsell MF, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006 Jan 19;354(3):261-9.
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16421367
Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol. 2007 Jul 10;25(20):2983-90.,http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17617530
Esophageal Cancer
Anderson SE, Minsky BD, Bains, M et al. Combined Modality Therapy in Esophageal
Hulscher JBF, van Sandick JW, de Boer A et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. NEJM 2002; 347:1662-1669.
Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349(23):2241-52.
Ilson DH. Oesophageal cancer: new developments in systemic therapy. Cancer Treatment Reviews 2003; 29: 525-532.
Gastric Cancer
Yao JC, Mansfield PF, Pisters PWT, et al. Combined-Modality Therapy for Gastric Cancer. Seminars in Surgical Oncology 2003; 21:223-227.
Lim L, Michael M, Mann GB, Leong T. Adjuvant therapy in gastric cancer. J Clin Oncol. 2005 Sep 1;23(25):6220-32. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16135489
Cunningham D, Allum WH, Stenning SP, Thompson JN, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16822992
Gastrointestinal Stromal Tumors
Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22(18):3813-25.
Head and Neck Cancer
Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001 Dec 27;345(26):1890-900.
Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004;22(9):1743-52.
Bonner JA, Harari PM, Giralt J, Azarnia N, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567-78. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16467544
D'Souza G, Kreimer AR, Viscidi R, Pawlita M, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007 May 10;356(19):1944-56. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17494927
Hepatocellular and Biliary Cancer
De Groen PC, Gores GJ, et al. Biliary tract cancers. NEJM 1999; 341:1368-1378.
Kummar S, Shafi NQ. Metastatic hepatocellular carcinoma. Clin Oncol (R Coll Radiol) 2003;15(5):288-94.
Hereditary Cancer
Burke W. Genetic testing. N Engl J Med 2002 Dec 5;347(23):1867-75.
Lynch HT, Snyder CL, et al. Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. JCO 2003;21(4): 740-753.
Khoury MJ, McCabe LL and McCabe ERB. Genomic Medicine: Population Screening in the Age of Genomic Medicine. N Engl J Med 2003 Jan 2;348(1):50-8.
American Society of Clinical Oncology Policy Statement Update: genetic testing for cancer susceptibility. JCO 2003;21(12): 2397-2406.
Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348:2339-2347.
Lynch HT, Snyder CL, Lynch JF, et al. Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J Clin Oncol 2003;21(4):740-53.
Venkitaraman AR. A growing network of cancer-susceptibility genes. N Engl J Med 2003; 348:1917-1919.
Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348:919-932.
Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004;22(4):735-42.
Hodgkin's Disease
Viviani S and others. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. JCO14:1421, 1996.
R. Sankila and others. Risk of subsequent malignant neoplasms among 641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. JCO 14:1442, 1996
Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99: 4283-4297. http://www.bloodjournal.org/cgi/content/full/99/12/4283?maxtoshow=&HITS=100&hits=100&RESULTFORMAT=1&searchid=1067831154517_8052&stored_search=&FIRSTINDEX=0&flag=HWREVIEW&sortspec=relevance&fdate=1/1/2002&journalcode????!? ???!
Diehl V. Advanced Hodgkin's disease: ABVD is better, yet is not good enough! J Clin Oncol 2003;21(4):583-5.
Imaging Studies
Van Den Bossche B, Van de Wiele C. Receptor imaging in oncology by means of nuclear medicine: current status. J Clin Oncol 2004;22(17):3593-607.
Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22(14):2942-53.
Infectious Disease in Cancer Patients
P.A. Pizzo. Management of fever in patients with cancer and treatment-induced neutropenia. NEJM 328:1323, 1993.
Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003; 101: 3365-3372.
Islet Cell Carcinoma
C.G. Moertel and others. The management of patients with advanced carcinoid tumors and islet cell carcinoma. Am. Intern. Med. 120: 302, 1994.
Kaposi's Sarcoma
Friedman-Kien and others. Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi's sarcoma. J Am Acad Derm 22:1237, 1990.Helphttp://Help
Kroll MH and Shandera WX. AIDS-associated Kaposi's sarcoma. Hospital Practice 1998;33:85-88,95-96,99-102.
A.E. Friedman-Kien and others. Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi's sarcoma. J Am Acad Derm 22:1237, 1990.
Antman K and Chang Y. Kaposi's sarcoma. NEJM 2000; 342:1027-1038.
Leukemia, Acute Lymphoblastic
Goldberg JM, Silverman LB, et al. Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium experience. JCO 2003;21(19): 3616-3622.
Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350(15):1535-48.
Rowe JM, Goldstone AH. How I treat acute lymphocytic leukemia in adults. Blood. 2007 Oct 1;110(7):2268-75. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17596539
Leukemia, Acute Myelogenous
Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. NEJM 1994;331:896-903.
Auerbach M. Acute myeloid leukemia in patients more than 50 years of age: special considerations in diagnosis, treatment, and prognosis. Am. J. Med. 1994; 96:180.
Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. NEJM 1995; 332: 217-223.
Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997; 89:3323-3329.
Lowenberg B, Downing JR and Burnett A. Acute myeloid leukemia. NEJM 1999;341:1051-1062.
Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002 Feb 1;99(3):759-67. http://www.bloodjournal.org/cgi/content/full/99/3/759?maxtoshow=&HITS=100&hits=100&RESULTFORMAT=1&searchid=1067831154517_8052&stored_search=&FIRSTINDEX=0&flag=HWREVIEW&sortspec=relevance&fdate=1/1/2002&journalcode=b????!? ???!
Leukemia, Childhood
Pui C-H. Childhood leukemias. NEJM 332:1618, 1995.
Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000 Jul 1;96(1):24-33. http://www.bloodjournal.org/cgi/content/full/96/1/24
Leukemia, Chronic Lymphocytic
Sorensen JM, Vena DA, Fallavollita A, et al. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the Group C protocol mechanism of the National Cancer Institute: five-year follow-up report. JCO1997;15:458-465
Mavromatis B, Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. JCO 2003;21(9): 1874-1881.
Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004;103(12):4389-95.
Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005 Feb 24;352(8):804-15. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15728813
Leukemia, Chronic Myelocytic
Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001 Nov 15;98(10):3074-81. http://www.bloodjournal.org/cgi/content/full/98/10/3074
Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. 2002 NEJM 346:645-652. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11870241
Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. NEJM 2003; 349:1451-1464.
Deininger MWN, O'Brien SG, et al. Practical management of patients with chronic myeloid leukemia receiving Imatinib. JCO 2003;21(8): 1637-1647.
Druker BJ, Guilhot F, O'Brien SG, Gathmann I, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 7;355(23):2408-17. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17151364
Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med. 2006 Jun 15;354(24):2542-51.,http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16775240
Leukemia, General
PS Gill and others. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. NEJM 332: 1744, 1995.
AS Freedman. Cell surface antigens in leukemias and lymphomas. Cancer Invest. 14:252, 1996.
Papenhausen PR, Moscinski LC et al. Cytogenetic and molecular evaluation in myelodysplastic syndrome and in acute and chronic leukemia. Cancer Control 1997; 4:389-398.
Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. JCO1997;15: 1767-1777.
Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000 Jun 1;95(11):3273-9. http://www.bloodjournal.org/cgi/content/full/95/11/3273
Ney PA, D'Andrea AD. Friend erythroleukemia revisited. Blood 2000 Dec 1;96(12):3675-80. http://www.bloodjournal.org/cgi/content/full/96/12/3675
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002 Oct 1;100(7):2292-302. http://www.bloodjournal.org/cgi/content/full/100/7/2292?maxtoshow=&HITS=100&hits=100&RESULTFORMAT=1&searchid=1067831154517_8052&stored_search=&FIRSTINDEX=0&flag=HWREVIEW&sortspec=relevance&fdate=1/1/2002&journalcode????!? ???!
Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003; 348:1777-1785. ,
Leukemia, Hairy Cell
Saven A and Piro LD. Treatment of hairy cell leukemia. Blood 79:1111, 1992.
Lung Cancer
Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. NEJM 2002; 346:92-98.
Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002 Jul 15;20(14):3054-60.
Ost D, Fein AM, Feinsilver SH. The solitary pulmonary nodule. N Engl J Med 2003;348(25):2535-42.
Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22(2):330-53.
Videtic GMM, Stitt LW, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. JCO 2003;21(8): 1544-1549.
Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350(4):379-92.
Arriagada R, Bergman B, Dunant A, Le Chevalier T, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14736927
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16014882
Winton T, Livingston R, Johnson D, Rigas J, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23;352(25):2589-97. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15972865
Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24;352(8):786-92. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15728811
Sandler A, Gray R, Perry MC, Brahmer J, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17167137
International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006 Oct 26;355(17):1763-71. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17065637
Slotman B, Faivre-Finn C, Kramer G, Rankin E, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007 Aug 16;357(7):664-72. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17699816
Lymphoma, non-Hodgkin's
R. I. Fisher and others. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. NEJM 328:1002, 1993.
MA Shipp, MD Abeloff, KH Antman et al. International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphoma: report of the jury. JCO 17:423, 1999.
Kuppers R, Klein U, et al. Cellular origin of human B-cell lymphomas. NEJM 1999;341:1520-1529.
Harris NL, Jaffe ES, Armitage JO et al. Lymphoma classification: from R.E.A.L. to W.H.O. and beyond. PPO Updates, Principles and Practice of Oncology 1999;13:1-14.
Siegel RS, Pandolfino T, Guitart J, Rosen S, et al. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000 Aug;18(15):2908-25.
Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000 Jul 15;96(2):410-9. http://www.bloodjournal.org/cgi/content/full/96/2/410
Pandolfino TL, Siegel RS, Kuzel TM, Rosen ST, et al. Primary cutaneous B-cell lymphoma: review and current concepts. J Clin Oncol 2000 May;18(10):2152-68.
Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000 Dec 1;96(12):3681-95. http://www.bloodjournal.org/cgi/content/full/96/12/3681
Lee EJ, Petroni GR, Schiffer CA, et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 2001 Oct 15;19(20):4014-22.
van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 2001 Mar 15;19(6):1855-64.
Kouroukis CT, Browman GP, Esmail R, Meyer RM. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review. Ann Intern Med 2002 Jan 15;136(2):136-43.
Hunault-Berger M, Ifrah N, Solal-Celigny P. Intensive therapies in follicular non-Hodgkin lymphomas. Blood 2002; 100: 1141-1152. http://www.bloodjournal.org/cgi/content/full/100/4/1141?maxtoshow=&HITS=100&hits=100&RESULTFORMAT=1&searchid=1067831154517_8052&stored_search=&FIRSTINDEX=0&flag=HWREVIEW&sortspec=relevance&fdate=1/1/2002&journalcode????!? ???!
Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002 Aug 15;20(16):3545-57. ,
Kutok JL, Aster JC. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol 2002 Sep 1;20(17):3691-702.
Hunault-Berger M, Ifrah N, Solal-Celigny P. Intensive therapies in follicular non-Hodgkin lymphomas. Blood 2002 Aug 15;100(4):1141-52.
Coiffier B, Lepage E, Brière J, et al. CHOP Chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. NEJM 2002; 346:235-242.
Sánchez-Beato M, Sánchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood 2003; 101: 1220-1235. http://www.bloodjournal.org/cgi/content/full/101/4/1220
Armitage JO, Carbone PP, et al. Treatment-related myelodysplasia and acute leukemia in Non-Hodgkin's lymphoma patients. JCO 2003;21(5): 897-906.
Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood 2003; 101: 2464-2472. http://www.bloodjournal.org/cgi/content/full/101/7/2464
Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003; 101: 391-398.,http://www.bloodjournal.org/cgi/content/full/101/2/391
Kaminski MS, Tuck M, Estes J, Kolstad A, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005 Feb 3;352(5):441-9. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15689582
Lymphoma, T Cell
PS Gill and others. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. NEJM 332: 1744, 1995.
Diamandidou E, Cohen PR, Kurzrock R. Mycosis Fungoides and Sézary Syndrome. Blood 1996;88: 2385-2409.
Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell Lymphoma: A distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996;88:4265-4274.
Siegel RS, Pandolfino T, Guitart J, Rosen S, et al. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000 Aug;18(15):2908-25.
Melanoma
Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001 Aug 15;19(16):3635-48.
Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002 Apr 1;20(7):1818-25.
Kirkwood JM, Bender C, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. JCO 2002;20(17): 3703-3718.
Bleicher RJ, Essner R, et al. Role of sentinel lymphadenectomy in thin invasive
cutaneous melanomas. JCO 2003;21(7): 1326-1331.
Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351(10):998-1012.
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006 Sep 28;355(13):1307-17. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17005948
Merkel Cell Carcinoma
Tai PT, Yu E, Winquist E, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 2000 Jun;18(12):2493-9.
Goessling W, McKee PH, Mayer RJ. Merkel cell carcinoma. J Clin Oncol 2002 Jan 15;20(2):588-98.
Mesothelioma
Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma: results in 120 consecutive patients. Ann Surg 1996;224:288-294.
Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005 Oct 13;353(15):1591-603. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16221782
Molecular Biology
Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000 May;18(9):1967-79.
de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000 Jan;18(1):204-13.
Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000;18(21):3707-21.
Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 2000 Aug 1;96(3):808-22. http://www.bloodjournal.org/cgi/content/full/96/3/808
Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000 Nov 15;96(10):3343-56. http://www.bloodjournal.org/cgi/content/full/96/10/3343
Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 2002 Jan 15;99(2):409-26.
http://www.bloodjournal.org/cgi/content/full/99/2/409
Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002 Sep 15;20(18 Suppl):1S-13S.
Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002 Sep 15;20(18):3906-27.
Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100: 1532-1542. http://www.bloodjournal.org/cgi/content/full/100/5/1532?maxtoshow=&HITS=100&hits=100&RESULTFORMAT=1&searchid=1067831154517_8052&stored_search=&FIRSTINDEX=0&flag=HWREVIEW&sortspec=relevance&fdate=1/1/2002&journalcode????!? ???!
Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin Oncol 2002 Apr 1;20(7):1932-41.
Mohr S, Leikauf GD, Keith G, Rihn BH. Microarrays as cancer keys: an array of possibilities. J Clin Oncol 2002 Jul 15;20(14):3165-75.
Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002 Jul 1;20(13):3001-15,
Pedersen-Bjergaard J, Andersen MK, et al. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia Blood 2002; 99: 1909-1912. http://www.bloodjournal.org/cgi/content/full/99/6/1909?maxtoshow=&HITS=100&hits=100&RESULTFORMAT=1&searchid=1067831154517_8052&stored_search=&FIRSTINDEX=0&flag=HWREVIEW&sortspec=relevance&fdate=1/1/2002&journalcode=????!? ???!
Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99(12):4283-97.
Venkitaraman AR. A growing network of cancer-susceptibility genes. N Engl J Med 2003;348(19):1917-9.
Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003; 348:1777-1785.
Hahn WC. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 2003 May 15;21(10):2034-43.
Peltomäki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. JCO 2003;21(6): 1174-1179.
Chen Y-C, Hunter DJ. Molecular epidemiology of cancer. CA Cancer J Clin 2005;55:45-54. http://caonline.amcancersoc.org/cgi/content/abstract/55/1/45?etoc
Multiple Myeloma
Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 2000 Sep 15;96(6):2037-44. http://www.bloodjournal.org/cgi/content/full/96/6/2037
Berenson JR, Hillner BE, et al. American Society of Clinical Oncology Clinical Practice Guidelines: The role of bisphosphonates in multiple myeloma. JCO 2002;20(17): 3719-3736.
Kyle, RA, Therneau, TM, et al. A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance. NEJM 2002; 346(8):564-569
Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104(3):607-18.
Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103(1):20-32.
Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004 Oct 28;351(18):1860-73. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15509819
Richardson PG, Sonneveld P, Schuster MW, Irwin D, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16;352(24):2487-98. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15958804
Barlogie B, Tricot G, Anaissie E, Shaughnessy J, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 9;354(10):1021-30. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16525139
Kyle RA, Therneau TM, Rajkumar SV, Larson DR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006 Mar 30;354(13):1362-9. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16571879
Bladé J. Clinical practice. Monoclonal gammopathy of undetermined significance. N Engl J Med. 2006 Dec 28;355(26):2765-70.,http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17192542
Bruno B, Rotta M, Patriarca F, Mordini N, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007 Mar 15;356(11):1110-20. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17360989
Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007 Jun 21;356(25):2582-90. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17582068
Kyle RA, Yee GC, Somerfield MR, Flynn PJ, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007 Jun 10;25(17):2464-72. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17515569
Myelodysplastic Syndromes
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088
Heaney ML and Golde DW. Myelodysplasia. NEJM 1999;340:1649-1660.
Molldrem JJ, Leifer E, Bahceci E et a. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Internal Med 2002;137(3):E156-E163.
Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21(5):897-906.
List A, Dewald G, Bennett J, Giagounidis A, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006 Oct 5;355(14):1456-65. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17021321
Myelofibrosis with Myeloid Metaplasia
Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. JCO 1999; 17:2954.
Tefferi A. The forgotten myeloproliferative disorder: myeloid metaplasia. The Oncologist 2003;8(3):225-231.,http://theoncologist.alphamedpress.org/cgi/content/full/8/3/225
Ocular Cancers
Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996;114: 1321-1328.
Harbour JW, Char DH, Kroll S, et al. Metastatic risk for distinct patterns of postirradiation local recurrence of posterior uveal melanoma. Ophthalmology 1997;104:1785-1792.
Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997;278: 1262-1267.
The Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma: COMS report no. 5. Arch Ophthalmol 1997;115:1537-1544.
Fishburne BC, Wilson DJ, Rosenbaum JT, et al. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997;115:1152-1156.
The Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma: COMS Report No. 4. Arch Ophthalmol 1997;115:886-893.
Rudoler SB, Corn BW, Shields CL, et al. Functional vision is improved in the majority of patients treated with external-beam radiotherapy for choroid metastases: a multivariate analysis of 188 patients. JCO1997;15: 1244-1251.
Finger PT. Microwave thermo-radiotherapy for uveal melanoma: results of a 10-year study. Ophthalmology 1997;104: 1794-1803.
Oncologic Emergencies
A. Yellin and others. Superior vena cava syndrome. The myth--the facts. Am Rev Respir Dis 141(5 Pt 1):1114, 1990.
DA Loblaw and NJ Laperriere. Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. JCO 1998;16:1613-1624.
Schindler N and Vogelzang RL. Superior vena cava syndrome. Experience with endovascular stents and surgical therapy. Surg Clin N Am 1999;79:683-694.
Ovarian Cancer
McGuire WP III. Current status of taxane and platinum-based chemotherapy in ovarian cancer. JCO 2003;21: 133s-135s.
Kaku T, Ogawa S, Kawano Y, et al. Histological classification of ovarian cancer. Med Electron Microsc. 2003;36(1):9-17.
Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. JCO 2003;21(6): 1180-1189.
Cannistra SA. Cancer of the ovary. N Engl J Med. 2004 Dec 9;351(24):2519-29.
Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004 Dec 9;351(24):2489-97.
Armstrong DK, Bundy B, Wenzel L, Huang HQ, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43.
Tropé C, Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J Clin Oncol. 2007 Jul 10;25(20):2909-20. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17617522
Pancreatic Cancer
Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007 Jun 20;25(18):2607-15. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17577041
Paraneoplastic Syndromes
Ashour AA, Verschraegen CF, Kudelka AP, et al. Paraneoplastic syndromes of gynecologic neoplasms. JCO1997 Mar;15(3):1272-82.
Levin KH. Paraneoplastic neuromuscular syndromes. Neurol Clin 1997 Aug;15(3):597-614,
Staszewski H. Hematological paraneoplastic syndromes. Semin Oncol 1997 Jun;24(3):329-33,
Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. NEJM 2003; 349:1543-1554.
Polycythemia Vera
Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100: 4272-4290.
Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc 2003; 78: 174-194.
Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006 Dec 7;355(23):2452-66. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17151367
Pregnancy and Hematology-Oncology
Berry, DL, Theriault, RL, et al. Management of breast cancer during pregnancy using a standardized protocol. JCO 1999; 17:855-861.
Webert KE, Mittal R, Sigouin C, et al. A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood 2003;102(13):4306-11
Alexander A, Samlowski WE, Grossman D, et al. Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol 2003;21(11):2179-86.
Oehler MK, Wain GV, Brand A. Gynaecological malignancies in pregnancy: a Aust N Z J Obstet Gynaecol 2003;43(6):414-20.
Green DM, Whitton JA, et al. Pregnancy outcome of partners of male survivors of childhood cancer: a report from the childhood cancer survivor study. JCO 2003;21(4): 716-721.
Prostate Cancer
Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001 May 3;344(18):1373-7. ,
Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21(2):383-91.
Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. NEJM 2003; 349:366-381.
Wilkinson S, Chodak GW. Critical review of complementary therapies for prostate cancer. JCO 2003;21(11): 2199-2210.
Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, et al. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005 May 12;352(19):1977-84. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15888698
Pisansky TM. External-beam radiotherapy for localized prostate cancer. N Engl J Med. 2006 Oct 12;355(15):1583-91.,http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17035651
Radiotherapy
J Crossen and others. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. JCO 1994; 12:627. ,
Ma BBY, Bristow RG, et al. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. JCO 2003;21(14): 2760-2776.
Renal Cell Carcinoma
Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol 2003;4(5):385-90.
Lam JS, Shvarts O, Pantuck AJ. Changing concepts in the surgical management of renal cell carcinoma. Eur Urol 2004;45(6):692-705.
Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005 Dec 8;353(23):2477-90. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16339096
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med. 2007 May 31;356(22):2271-81. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17538086
Escudier B, Eisen T, Stadler WM, Szczylik C, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):125-34. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17215530
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115-24. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17215529
Sarcoma
Arndt CAS and Crist WM. Common musculoskeletal tumors of childhood and adolescence. NEJM 1999;341:342-352.
Pappo AS, Meza JL, et al. Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from Intergroup Rhabdomyosarcoma Studies III and IV. JCO 2003;21(4): 638-645.
Oliveira AM, Fletcher CD. Molecular prognostication for soft tissue sarcomas: are we ready yet? J Clin Oncol 2004;22(20):4031-4.
Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005 Aug 18;353(7):701-11. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16107623
Skin Cancer
Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001 Mar 29;344(13):975-83.
Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681-1691.
Statistics
MB Shimkin and others. Survival in untreated and treated cancer. Ann Intern Med 45:355, 1956.
Jemal A, Tiwari RC, Murray T, et al. Cancer Statistics, 2004. CA Cancer J Clin 2004; 54:8-9. http://caonline.amcancersoc.org/cgi/content/full/54/1/8
Supportive Care
MH Levy and R.B. Catalano. Control of common physical symptoms other than pain in patients with terminal disease. Semin Oncol 1985; 12:411.
KM Foley and others. The treatment of cancer pain. NEJM 1985; 313:84.
MH Levy. Pharmacologic treatment of cancer pain. NEJM 1996;3351124-1132.
Grallo RJ et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. JCO 1999; 17:2971.
Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000 Apr;18(7):1570-93.RL Koretz. Parenteral nutrition: Is it oncologically logical? JCO 1984; 2:534.
Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 2001 Feb 1;19(3):895-908.
Rozans M, Dreisbach A, et al. Palliative uses of methylphenidate in patients with cancer: A review. JCO 2002;20:335-339.
Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002 Jan 1;20(1):348-52.
Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349(20):1943-53.
McNicol E, Strassels S, Goudas L, et al. Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain. J Clin Oncol 2004;22(10):1975-92.
Spielberger R, Stiff P, Bensinger W, Gentile T, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004 Dec 16;351(25):2590-8. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15602019
Davis MP, Dreicer R, Walsh D, et al. Appetite and cancer-associated anorexia. J Clin Oncol 2004;22(8):1510-7.
Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007 Jul 20;25(21):3158-67. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17634496
Testicular Cancer
Bosl GJ, Motzer RJ. Medical progress: testicular germ-cell cancer. NEJM 1997;337(4)
Vaughn DJ, Gignac GA, Meadows AT. Long-term medical care of testicular cancer survivors. Ann Intern Med 2002 Mar 19;136(6):463-70.
Einhorn LH, Williams SD, Chamness A, Brames MJ, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007 Jul 26;357(4):340-8. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17652649
Thyroid Cancer
MJ Schlumberger. Papillary and follicular thyroid carcinoma. NEJM 1998; 338: 297.
Skinner MA, Moley JA, Dilley WG, Owzar K, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005 Sep 15;353(11):1105-13. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16162881
Tobacco
American Society of Clinical Oncology policy statement update: tobacco control--reducing cancer incidence and saving lives. 2003. J Clin Oncol 2003;21(14):2777-86.
Tumor Markers
SE Bates. Clinical application of serum tumor markers. Ann. Int. Med. 115:623, 1991
Gadducci A, Cosio S, Carpi A, et al. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 2004;58(1):24-38.
Unknown Primary
Bitran JD and Ultmann JE. Malignancies of undetermined primary origin. Disease-A-Month (April, 1992), p. 215.
Hainsworth JD and Greco FA. Treatment of patients with cancer of an unknown primary site. NEJM 1993; 329:257.
Hainsworth JD, Erland JB, Kalman LA et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. JCO 1997;15:2385-2393.
Culine S, Lortholary A, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: Results of a randomized Phase II study-Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). JCO 2003;21(18): 3479-3482.
Vaccines
Greten, TF and Jaffee, EM. Cancer Vaccines. JCO 1999; 17:1047-1060.
Ribas A, Butterfield LH, et al. Current developments in cancer vaccines and cellular immunotherapy. JCO 2003;21(12): 2415-2432.
Waldenström's Macroglobulinemia
Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000 Jan;18(1):214-26.